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Abstract 
‘Evolutionary medicine’ has been proposed as an alternative treatment of infectious 
diseases in response to the emergence of multidrug resistant bacterial pathogens and to the 
limited availability of new antibiotics. Among potential treatments, microbial “Trojan horses” 
are a way of deploying weaknesses in microbial populations by invading them with tailor-made 
bacteria (e.g. sensitive to antibiotics). Here I exploit the fitness cost linked to the production of 
the siderophore pyoverdine in the human pathogen Pseudomonas aeruginosa for population 
invasion. Individuals in a population that do not produce the siderophore do not pay the cost 
and can overtake a population. However, cooperative individuals are preserved by the presence 
of structure in the population (e.g. growth in biofilms) that limits the diffusion of pyoverdine, 
therefore preventing the invasion by non-cooperators. I overcame this limitation by altering the 
individual benefit acquisition through the deletion and/or overexpression of pyoverdine 
primary (FpvA) and secondary receptors (FpvB). I characterised growth and pyoverdine 
production strategies in iron limited conditions in a variety of scenarios in both monocultures 
and competition experiments against the wildtype MPAO1. My results show that the selective 
manipulation of pyoverdine receptors leads to different evolutionary dynamics in the 
population, which are dependent on the relationship between costs of pyoverdine production 
and benefits of reception during balanced growth, as well as in the kinetics of this process prior 
to exponential growth. These strategies change in response to environmental inputs such as the 
presence of a stressor and are maintained when cells grow in biofilms and during infections of 
Galleria mellonella, both of which are representative of structured environments. By 
interfering with the complex regulatory network of pyoverdine production and reception, I 
produced strains with optimised investments under certain conditions that successfully displace 
a wildtype population therefore paving the way for their use as ‘Trojan horses’ for population 
control.  
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1.1-Darwinian medicine 
 
The World Health Organization (WHO) has raised the alarm due to the emergence 
of pathogens displaying increased antibiotic resistance, while we experience a sustained 
shortage of new effective drugs. In addition, these resistance mechanisms tend to persist 
within bacterial populations over long periods of time, given that the cost of carrying 
them, even in the absence of antibiotics is minimal, and usually compensated by 
secondary mutations (1–3). Apart from the discovery of new antibiotics, combinations of 
existing antibiotics have been used to enhance their microbicidal activity and to prevent 
emergence of resistance mechanisms with partial success, and they require further clinical 
research (4–6). Moreover, the evidence gathered in recent years points to horizontal gene 
transfer as the main mechanism responsible for the fast spread of antibiotic resistance, 
what makes antibiotic treatments even less effective (7). One of the suggested alternatives 
to tackle this problem is the so called “Evolutionary medicine” (also known as 
“Darwinian medicine”-DM-), which aims to “predict  and  manipulate  microbial  effects  
on  human  health  by  integrating  ecology,  evolutionary  biology,  microbiology,  
bioinformatics,  and  clinical  expertise” (8).  
As a developing area, DM has challenged some of the traditional assumptions when 
using antibiotics. Traditionally, antibiotic treatments tend to administer the highest 
tolerable dose, hoping to eliminate sensitive and partially sensitive strains. Under the 
scope of DM, this approach could lead to the emergence of high-level resistant pathogens 
under specific conditions (9). Understanding how bacterial communities behave and 
evolve during infection could help to increase the lifespan of antibiotics while reducing 
the emergence of resistances. For example, the efficiency of antibiotics can be modulated 
by population size, e.g. through environmental pH alterations caused by the bacterium, in 
such a way that successful treatment protocols become ineffective at high cell density 
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(10). Interestingly, the modification of dosage strategies can reduce the effects in the 
antibiotic due to those pH alterations (10). Traditionally, one would not consider anything 
but early treatment. Nevertheless, knowledge gained in the evolutionary field predicts 
that a potential early initiation of a treatment may not be the best strategy to prevent the 
emergence and spread of drug-resistance (11). Currently, restriction of antibiotics is 
viewed as a tool to combat the spread of resistances. Yet, restriction of antibiotics (used 
as a last resort) when multiple resistances exist for alternative antibiotics might facilitate 
the emergence of multi-drug resistant (MDR) strains (12). Finally, the use of 
combinations of synergistic antibiotics is preferred in clinical settings, but, when 
analyzing the evolutionary outcomes,  the use of antagonistic antibiotics might be more 
efficient in preventing the emergence of resistance (13).  
DM not only challenges current approaches, but also provides with innovative 
solutions such as the exploitation of collateral sensitivity, which is defined as the 
emergence of sensitivity to an antibiotic when strains become resistant to another one 
(14).  This has led to treatments in the form of sequential cycles of different antibiotics to 
which sensitivities emerge when treated with another one (14). Nevertheless, in the same 
way that sensitivities are generated, cross-resistances emerge as a consequence of the 
same treatments, depending on the evolutionary paths of the process (15). Other 
approaches lie beyond the use of traditional antibiotics. For example, the DNA 
translocase Mfd, which is highly conserved across phyla, is considered as an “evolvability 
factor” and its inactivation decreases the emergence of resistant genotypes (16). 
Another approach taken by DM focuses on targeting virulence factors with the aim 
to generating less virulent strains. Although resistance mechanisms can also emerge, the 
increase in frequency and spread of persistence could be reduced under specific 
environmental conditions when compared to traditional antibiotics (17,18). Among 
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virulence factors, those that provide a collective benefit have become a major area of 
research. These secreted molecules, although costly to produce and secrete, provide an 
extensive benefit to the whole community. Termed as “public goods”, they are open to 
exploitation by members of the community who do not produce and secrete them, 
therefore saving the costs of their production while benefitting from them.  
1.2-Cooperation and cheating in microbial populations 
 
Cooperation is a social strategy that includes mutualistic and altruistic behaviours, 
as it is defined as a fitness improvement of the recipient regardless of the fitness change 
of the actor (19).  One of the cooperative strategies in bacteria involves the secretion of 
public goods but this act is open to exploitation (20). Cheating emerges from selfish 
individuals (cheaters/cheats) appearing in the population, obtaining benefits from a 
collectively produced public good without paying the fitness costs involved in the 
production and secretion. The emergence and preservation of cooperation remains as one 
of the major dilemmas in biology, as the relative fitness of the cooperative individuals is 
reduced when following these cooperative strategies, thus not being favored by evolution 
(19). There is a wide range of described public goods that participate in different scenarios 
with the same goal of offering a fitness advantage to the community. These are among 
others: Siderophores, antibiotic-degrading enzymes, toxins against other competitive 
bacteria, the multiple components required for biofilm formation, regulatory molecules 
and proteases (21–25). 
There is a number of mechanisms by which bacteria favor cooperative strategies 
even in the presence of cheaters, including amongst others but not limited to: policing, 
metabolic prudence and growth in structured environments (Fig. 1.1) (26). These are 
important, because in the absence of mechanisms that regulate non-cooperative 
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behaviours, cheaters may overtake the whole population, which would eventually lead to 
its extinction due to the loss of an essential public good (27). Metabolic prudence is a 
strategy in which  cooperative cells adjust the timing of secretion of public goods, so they 
are only produced when the costs and the impact on individual fitness are minimal while 
there is another limiting component, therefore preventing cheaters from obtaining a 
greater fitness advantage (24). Policing strategies imply the penalization of cheating 
individuals. Having a public good linked to the production of a toxin – and the 
corresponding anti-toxin – guarantees that those that do not produce the public good, are 
more penalized than those that do produce it (23).  
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Figure 1.1. Strategies to block cheater dominance in single-trait scenarios. (A) 
Quorum sensing (QS): Bacteria secrete public goods only when a defined level of cell density is 
attained (quorum), reaching determined concentration values of signalling molecules. (B) Partial 
privatization: Prioritized access to public goods. (C,I) Policing via direct harm: Coupled 
production of a public good with damaging element and its corresponding resistance system. 
(Panel II) Policing via reciprocity. In a public good exchange relationship, a party can 
downregulate their own production to reciprocate the nonproducer. (D) Facultative 
cooperation/metabolic prudence: cells secrete public goods adjusting the timing, so they are only 
produced when the costs and impact on individual fitness are minimal, while there is another 
limiting component (E) Spatial structure. the matrix prevents the free diffusion of public goods, 
that remain nearby cooperative clonal individuals. (F) Antagonistic pleiotropy: Coordinated 
production of a public and a private goods, limiting cheater access only to the public good. Taken 
from (20). 
 
 
As mentioned before, one of the mechanisms for cheater control results from the 
growth in structured populations. In nature, bacteria tend to form biofilms: a secreted 
matrix in which bacteria are embedded (28). This matrix presents a complex composition, 
including exopolysaccharides, DNA, surfactants, proteins and adhesive fibers amongst 
other constituent molecules (29). This form of life offers, from a traditional point of view, 
an elevated survival under stress conditions (presence of antibiotic or phages, starvation, 
mechanical aggression, etc), while stablishing complex social interactions from which 
division of labour may emerge (29–31). From a social perspective, biofilms offer a control 
mechanism to prevent cheater dominance and community collapse, given that the matrix 
prevents the free diffusion of public goods that remain nearby cooperative clonal 
individuals (32,33). Indeed, the production of the matrix, another cheatable component, 
becomes an advantage in the social context as producing members are pushed further up 
in the 3D structure, facilitating the acquisition of nutrients and resistance to mechanical 
aggression (34,35). 
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1.3-Pseudomonas aeruginosa  
 
Pseudomonas aeruginosa is a heterotrophic, gram negative bacterium, a facultative 
anaerobe that can grow via aerobic respiration or anaerobic respiration with nitrate as the 
terminal electron acceptor (36). P. aeruginosa grows at 37 °C although it is able to survive 
in temperatures ranging from 4 to 42 °C (36). P. aeruginosa has the ability to grow on 
more than 100 molecules as the sole carbon source reflecting its metabolic flexibility. 
Although it is a relatively common environmental bacterium, it is also detected in water-
reservoirs including sinks in hospitals and in domestic dwellings (36). P. aeruginosa 
possesses a large genome (≈6.3Mb) which provides the bacterium with the plasticity to 
survive in these multiple environments (37). 
 
1.3.1-Pseudomonas aeruginosa clinical relevance 
As a result of this genetic flexibility, P. aeruginosa has become an opportunistic 
human pathogen. According to the Center for Disease Control and Prevention (CDC), as 
of 2014, nine percent of the nosocomial acquired infections in the United States of 
America were caused by P. aeruginosa resulting into  51.000 nosocomial infections per 
year, of which around 11% present multiple drug resistance (MDR), leading to 400 deaths 
annually (38). 
P. aeruginosa can be found in normal flora colonising different niches like the skin, 
the digestive system and the nasal mucosa or the throat.  Different environments alter the 
colonisation prevalence rates, but when cutaneous or mucosal barriers (e.g: burn wounds, 
catheters, or due to the use of mechanical ventilation) are damaged, these can be increased 
to 50% from barely 2% in the skin as well as to up to 24% found in faecal samples (39). 
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Most of the hospital acquired pneumonias (86%) are defined as ventilator associated 
pneumonias (VAP) (40). Out of the different types of VAPs P. aeruginosa accounts for 
the highest mortality rate, as 50% of the patients die due to the infection caused by P. 
aeruginosa, and not due to the original pneumonia (41,42). Urethral catheters also help 
P. aeruginosa colonisation, causing urinary tract infections (UTI). P. aeruginosa is 
isolated in 12% of the UTI, being the third most frequent isolated microorganism for this 
type of infections in nosocomial settings (43).  
 Immunocompromised patients are ideal targets for P. aeruginosa hospital acquired 
infections. In neonatal intensive care, the risk of infections increases as immunodeficient 
infants require indwelling devices and/or parental nutrition, that facilitate bacterial 
growth in form of biofilms (44). Although transmission of P. aeruginosa via health 
workers is becoming increasingly important, the main sources of contamination are 
environmental, with water suspected to  be the natural reservoir for the bacterium (45–
47).  
 P. aeruginosa infections are of particular relevance for cystic fibrosis (CF) 
patients. CF is a hereditary, recessive and autosomal life-limiting disease caused by 
mutations in the CTFR gene encoding for an ABC transport ion channel involved in the 
transport of chloride though the epithelial membrane (48). Due to these special conditions 
in the lung of CF patients, P. aeruginosa is able to colonise and proliferate. In CF patients 
P. aeruginosa has arisen as the main cause of morbidity and mortality, implying that the 
great majority of the patients (above 80%)  die because of P. aeruginosa (49). In addition, 
P. aeruginosa presents a whole set of intrinsic and acquired antibiotic resistance 
mechanisms. Intrinsic mechanisms conferring resistance include reduced membrane 
permeability, efflux pump expression and production of beta-lactamases (50). 
Acquisition of antibiotic resistances can also be gained through mutations and horizontal 
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gene transfer that cause decreased antibiotic uptake, alteration of antibiotic targets (e.g 
ribosomes), increased expression of efflux pumps (e.g MexXY system)  and production 
of other antibiotic-inactivating enzymes (50). Moreover, P. aeruginosa is able to enter 
transient forms of life in which resistance to antibiotics is accentuated (biofilms and 
persister cells) (50). As a result, P. aeruginosa has been included by the World Health 
Organization as critical pathogen for which new antibiotics are urgently required (51). 
 
1.3.2-Pseudomonas aeruginosa as a model for social conflict studies 
 
P. aeruginosa is considered as a reference bacterium to study social behaviour. It 
possesses a very complex QS mechanism – a social mechanism by itself as shown in Fig. 
1.1 – regulating  multiple traits, many of which behave as social attributes due to the fact 
that they are secreted and in principle, available for all the members of the community 
(52). Example of these are the secreted virulence factors regulated by QS: elastase, 
proteases, alkaline protease, exotoxin, etc (53). Biofilms formation is another 
characteristic of P. aeruginosa and, as mentioned above, division of labour is key for the 
formation of these structures that help to improve responses to different aggressions 
(54,55). Biofilms are formed by secreted molecules open to exploitation by non-
cooperative individuals, such as rhamnolipids acting as biosurfactants, which grant access 
to water, oxygen and nutrients (24,56). Policing those that do not cooperate is another 
social behaviour present in P. aeruginosa communities and can be triggered by QS 
(23,57). 
When growing in iron restricted environments, P. aeruginosa secretes two main 
types of iron chelators: pyoverdine (primary and with higher iron affinity) and pyochelin. 
For over a decade, the  metabolically expensive pyoverdine system from P. aeruginosa 
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has been used as a reference model when it comes to study public goods, cooperation and 
competition in unstructured environments  (21). Some of the advantages of its use are 
common to bacteria, such as inexpensive maintenance and attainment of major 
evolutionary outcomes in short periods of time. Other advantages belong exclusively to 
P. aeruginosa, including the possibility to easily quantify pyoverdine and the vast amount 
of information about its chemical properties, synthesis and genetic regulation which are 
described in the later sections  (58). Pyoverdine is a complex molecule whose production 
involves severe metabolic investment. Once it is synthesized and secreted, it constitutes 
a public good and such is open to exploitation by non-producers, which naturally emerge 
in P. aeruginosa populations (59).  
In laboratory-controlled conditions, the dynamics of the pyoverdine system have 
helped to decipher the elementary components behind these social interactions. For 
example, the emergence of pyoverdine cheaters forces the remaining producer cells to 
partially compensate by increasing the synthesis of siderophore (60). However, if cheaters 
get fixed in the population, the cooperative phenotype is unlikely to be re-evolved even 
under favorable conditions  (61). The pyoverdine system has been used as a model for the 
analysis of other factors influencing the evolutionary outcomes of a population, such as 
the negative frequency dependence (cheats present increased relative fitness when its 
frequency is low in the population) and the negative effect of high cell densities on 
cooperation (62,63). 
As a relevant chronic pathogen for CF patients, several longitudinal studies have 
been conducted to understand how P. aeruginosa evolves in the lungs of the host. 
Although initially relevant to establish the infection, many of the aforementioned virulent 
social traits, like QS and pyoverdine, are downregulated (usually through mutations that 
eliminate the trait) (64). In the case of pyoverdine, mutations inactivating pvdS (the master 
11 
 
regulator of pyoverdine synthesis) are detected earlier than mutations inactivating the 
pyoverdine receptor, taking place once pyoverdine is not detectable in the environment 
(64). Following the inactivation of the pyoverdine system, the uptake of iron through 
heme is upregulated in a mechanism that is no longer consider ‘public’ but private since 
it can only benefit the producing strains (65). These three events: inactivation of synthesis, 
inactivation of reception and privatisation of iron uptake, suggest a social selective force. 
 
1.4-Pseudomonas aeruginosa siderophores 
 
Siderophores, molecules secreted to sequester iron from the environment, are 
amongst the multiple virulence factors produced by P. aeruginosa (66). In nature, iron is 
present in two forms, Fe2+ and Fe3+ with dissimilar solubilities. In aerobic environments, 
insoluble Fe3+ (ferric oxides) is the main form, in fact, the concentration of free iron (Fe3+) 
in an aerobic and neutral pH environment is ∼10−18 M, while bacteria require micromolar 
concentrations, which highlights the relevance of iron scavenging mechanisms for their 
survival (67).  In human hosts, a great part of the iron is sequestered: either into heme 
structures within the host cells or chelated by transferrin in fluids (68). Given that iron is 
essential for bacterial growth, bacteria have developed a plethora of mechanisms to obtain 
iron, like iron substitution, receptors for heme groups, hemophores, direct recognition of 
transferrin and iron chelators (69–73).  
Pyoverdine and pyochelin are the main siderophores that allow P. aeruginosa to 
obtain iron from the environment or the host. These molecules present different affinities 
for iron, being the pyoverdine´s affinity greater than pyochelin´s (74). In addition, P. 
aeruginosa can use  citrate  and heme mediated uptake of ferrous iron during CF lung 
infection through the FecA, Feo, Phu, and Has systems (75,76).  
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As seen on Fig. 1.2, pyoverdines are comprised of a conserved fluorescent 
dihydroxyquinolone chromophore, an acyl side chain bound to the chromophore and a 
variable peptide chain bound to the C1 carboxyl group of the chromophore (77). 
According to the peptidic chain structure it is possible to define three types of pyoverdines 
in P. aeruginosa (78). The synthesis of pyoverdine involves different stages taking place 
in the cytoplasm and the periplasm (Fig. 1.3) and involving non ribosomal peptides and 
periplasmic processes (79,80). The periplasmic steps require the PvdE ABC-transporter 
in order for pyoverdine to cross the inner membrane and an efflux pump (PvdRT-OpmQ) 
in charge of secreting the matured pyoverdine to the extracellular medium. However, the  
inactivation of the latter only reduces secretion down to 50-60%, which suggests that 
other export systems have to be present (81). Once the ferri-pyoverdine complex returns 
to the periplasmic compartment, iron is reduced and dissociated from pyoverdine via a 
recently discovered mechanism (82) and  allowing the pyoverdine to be reutilized, 
consistent with an expensive de novo synthesis (83).  
 
 
Figure 1.2: Chemical structures of pyoverdine (left) and pyochelin (right). Figures 
obtained and modified from www.pubchem.ncbi.nlm.nih.gov 
Peptide chain 
Dihydroxyquinolone 
Acyl chain 
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Such a costly production is tightly regulated. A depiction of the pyoverdine 
canonical regulation is presented on Fig 1.4 involving two main levels of regulation. In 
the first level, reduced intracellular iron concentration leads to the disassociation of Fur 
repressors from their binding site in multiple promoters, leading to the synthesis of PvdS, 
an extracytoplasmatic function sigma factor responsible of the transcription of the genes 
involved in pyoverdine synthesis, FpvI, another extracytoplasmatic function sigma factor 
required for the synthesis of pyoverdine receptor FpvA, and FpvR, a FpvA-membrane 
bound anti-sigma factor blocking both PvdS and FpvI activities (84,85). The second level 
involves ferripyoverdine binding to the FpvA receptor, leading to the anti-sigma factor 
FpvR cleavage by Rsep and ClpP (86), releasing PvdS and FpvI which induces the 
synthesis of pyoverdine, elastase, protease and the FpvA receptor (87,88). Therefore, 
pyoverdine synthesis is initially regulated by the environmental iron concentration and 
later by its own levels through interaction with its own receptor. Out of this canonical 
regulation, other regulatory interactions have been described: the FpvI sigma factor is 
able to upregulate both its own and pvdA transcription and similarly, PvdS regulates its 
own transcription (89). When enough iron has been accumulated inside the bacterium, 
the iron binds to Fur and the complex inhibits the transcription of all genes coding for 
proteins involved in iron acquisition (90). 
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Figure 1.3: Synthesis and secretion of pyoverdine (green hexagon). A primary scaffold 
named ferribactin is synthesized by the non-ribosomal peptide synthases (NRPS) PvdL, PvdI, 
PvdD, and the accessory enzymes (PvdH, PvdF, PvdA) producing the intermediate components. 
A myristic- or myristoleic acid side-chain is incorporated by the Module 1 of PvdL as the first 
constituent block. PvdE transports ferribactin into the periplasm, where the side chain is cleaved 
by PvdQ prior to the cyclization and maturation of the chromophore by PvdP, PvdO, PvdN/PtaA. 
The mature pyoverdine is then secreted to the surrounding environment by PvdRT-OpmQ efflux 
pump, which is also used for recycling. Taken from (58). 
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Figure 1.4: Regulation of pyoverdine production. (1) In the absence of iron, the Fur 
protein dissociates from the fpvI, pvdS and fpvR promoters, allowing their synthesis. (2) 
Therefore, fpvA and the pyoverdine synthesis genes are transcribed at a basal level. (3/4/5) When 
ferri-pyoverdine binds to FpvA, it results in the interaction between FpvA and FpvR causing 
proteolysis of the latter. (6) This proteolysis releases the sigma factors PvdS and FpvI, which 
recruit the RNA polymerase and lead to the increased expression of the receptor FpvA and the 
genes involved in the synthesis of pyoverdine, virulence factors (exotoxin A, and PrpL protease) 
and others. (7) When enough soluble iron is accumulated in the cytoplasm, Fur blocks the 
expression of fpvI, pvdS and fpvR and the system returns to its initial state. Taken and modified 
from (58) 
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1.5-Pyoverdine receptors: 
As described in the previous section, FpvA is defined as the main pyoverdine 
receptor. It belongs to the TonB-dependent transporters (TBDTs) family, which is highly 
variable in numbers among different bacteria. For example, only 7 genes belonging to 
this family have been identified in Escherichia coli, while there are 34 identified in P. 
aeruginosa (91). These receptors require the TonB protein (an energy-transducing 
protein) in order to carry out the active transport of molecules by coupling the energy of 
the cytoplasmic membrane to the receptors as in the case of the ferri-siderophores 
transported by FpvA (92). TonB forms a complex with the proteins ExbB and ExbD – 
both of which are required for a full TonB functionality – which are located on the inner 
membrane and protruding into the periplasmatic space. P. aeruginosa possesses three 
TonB proteins, being TonB1 mainly involved in iron transport (92). 
The structures of 12 other TBDTs involved in the uptake of different molecules 
(siderophore, B12 vitamin, nickel complexes and carbohydrates) in other bacteria have 
been described. They all present similar structures: a 22-stranded β-barrel to span the 
outer membrane with a ‘plug’ domain folded into the interior of the barrel  (91). FpvA 
and other TBDTs regulating signaling cascades after ligand binding possess an additional 
N-terminal domain, which is essential for signal transduction and not for transport. This 
extra domain of about  90  residues is located  in  the  periplasm, while the loop joining 
the signaling domain and the plug includes a sequence named Ton-box that constitutes 
the binding site of TonB1 upon ligand-receptor interaction (93). When FpvA is unloaded, 
the TonB-box interacts with the signaling domain, but once loaded with ferripyoverdine, 
structural changes allow the Ton-box-TonB interaction, transducing the energy that 
facilitates the signaling domain-FpvR interaction, making FpvR accessible to proteases 
and triggering the release of PvdS and FpvI (93).  
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There are specific receptors for each of the three types of pyoverdine: pyoverdine 
type I binds the FpvA receptor whereas the other two types of pyoverdines, bind the 
FpvAII and FpvAIII receptors that were identified in 2003 (95). In addition to the primary 
receptor, P. aeruginosa has a secondary pyoverdine receptor, named FpvB, with 54% 
similarity to FpvA. FpvB was discovered in 2004, and it acts independently of the primary 
receptor, although it can only transport type I pyoverdine (94). Contrary to FpvA, there 
is barely no information available about the role, structure or regulation of FpvB. Indeed, 
it is generally overlooked and excluded from the canonical description of the pyoverdine 
system. Despite this, it seems to play a role in the evolutionary dynamics of P. aeruginosa 
during infection, as reported by a recent  study that detected mutations in FptA (pyochelin 
receptor), FpvA, and FpvB among the 7 TBDTs inactivated during the adaptation of the 
strain to the lungs of CF patients (95) 
Mutations in different regions of the fpvA gene yield alterations in pyoverdine 
transport and synthesis. Indeed, although thought to be essential for pyoverdine synthesis, 
lower production of this siderophore is observed in the absence of FpvA, while 
maintaining  certain degrees of uptake (attributable to FpvB)  (96). 
 
1.6-Relevance of iron and pyoverdine: 
Iron is an essential element required for bacterial growth. Bound to proteins, it 
catalyzes cruzial physiological processes such as respiration, central metabolism and 
DNA repair, but at the same time, when it is in its free form, it is able to catalyse 
biomolecular damage to DNA, proteins and lipids via Fenton chemistry (97,98). In 
addition, iron is essential for the formation of P. aeruginosa biofilms (99), and the 
presence of chelators (natural or synthetic), limits the formation and development of these 
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type of structures (100–102). Studies have shown the importance of iron for P. aeruginosa 
subsistence: 177 genes out of 5500 displayed >2.0 fold deviations in their expression and 
1.3% of the genes showed >5.0 fold changes when going from iron starvation to iron 
supplementation in just 10 minutes (103). As such, upregulation of the expression of 
genes related to iron physiology is detected both in P. aeruginosa (e.g. iron chelators) and 
vertebrate models (e.g.  lactotransferrin and ferritin) while infection by the bacteria takes 
place (104). 
Given that iron is fundamental for bacteria growth and being pyoverdine the main 
iron chelator in P. aeruginosa, this molecule also plays a fundamental role in biofilm 
formation when iron is scarce (99). However, the role of pyoverdine in late CF stages is 
thought to be secondary, due to reduced oxygen levels causing iron to be in its soluble 
ferrous form which correlates with the inability of detecting pyoverdine in some patients 
and the lack of pyoverdine production in strains isolated from them (76,105). Indeed, as 
mentioned above, due to social conflicts emerging in the microbial community, P. 
aeruginosa switches to a privatized iron uptake system (heme) over time (65,106). Early 
stages of CF infection seem to provide researchers with a clearer picture of the role of 
pyoverdine during infection. For instance, 16 hours after the infection, heme, enterobactin 
and pyoverdine synthesis and acquisition genes are upregulated (104). In fact, during 
these early stages, the synthesis of pyoverdine allows P. aeruginosa to outcompete the 
iron chelators secreted by the host (104). Nevertheless, pyoverdine and pyochelin seem 
to have more relevance than heme during this early hours, as infection with the heme 
uptake-defective hasR phuR double mutant have lethality levels similar to that of the wild 
type whereas the  pyoverdine/pyochelin deficient double mutant, behaves avirulently 
(107). 
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The functions of pyoverdine are not limited to iron chelation. Although considered 
a virulence factor, it  can also be seen as a signaling molecule as once it binds its receptor, 
prompts a series of regulatory changes responsible for the production of multiple 
virulence factors (exotoxin A, PrpL exoprotease and pyoverdine itself) (87). In addition 
to this, pyoverdine is able to chelate multiple cations such as Al3+, Co2+, Cu2+  Eu3+, Ni2+, 
Pb2+, Tb3+ and Zn2+ from the extracellular milieu, reducing their uptake into the cytoplasm 
and therefore also reducing their toxic accumulation (108). In fact,  pyoverdine could bind 
certain metal oxides, which could help to establish a biofilm on different metal surfaces 
(including titanium, frequently used in medical devices) (109). Recently, a new role has 
been discovered for pyoverdine given that it is able to disrupt mitochondria (causing 
hypoxia) and iron homeostasis in Caernohabditis elegans just by mere exposure (110).  
 
1.7-Alternative ways to combat P. aeruginosa infections: The Trojan horse 
approach. 
 
In nature, Trojan horse strategies are used by different organisms to maximise their 
chances of survival. For example, Bacillus nematocida B16 lures C. elegans by producing 
volatile organic compounds making them the preferential dietary choice, just to invade 
and feed from the intestinal components of the nematode (111). 
Due to the lack of new antibiotics, new strategies to combat P. aeruginosa 
infections are required. Interestingly, iron chelators have already been used as Trojan 
horses in a strategy involving the artificial synthesis of antibiotics conjugated to 
siderophores (sideromycins) which become active once the conjugates are transported 
into the bacterium through the iron chelator receptors. This approach has been conducted 
with pyoverdine and pyochelin. As an example, an ampicillin-pyoverdine conjugate with 
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high antibacterial activity showed promising results against a P. aeruginosa ampicillin 
resistant strain (112). However, in a following work opposite results were obtained when 
conjugating cephalexin to pyoverdine (113), arguably due to the fact that the conjugate 
was unable to exert antibacterial activity due to steric impediments. A recent work 
managed to solve this problem using a beta-lactamic structure as a linker between the 
siderophore and the antibiotic in order to produce a conjugate that was delivered in a beta-
lactamase producing Acinetobacter baumanii strain (67). Pyochelin conjugates showed 
variable results, although none of them seemed to improve the efficiency of the free 
antibiotic (114). 
Another Trojan horse approach involves the suppression or modification of 
cooperative mechanisms leading to less virulent infections which usually are easier to 
eradicate (Fig. 1.5). The use of cheater strains taking advantage of public good production 
to invade virulent wildtype populations in medical intervention strategies has already 
been proposed (115). This eventual invasion would cause a reduction in size/virulence, 
or could either introduce sensitivity to antibiotics into the population or secrete toxins 
under the control of inducible promoters (115). 
Conflicting results have been described for the QS system. In vitro increase of the 
population structure using agar decreased cheater fitness (116). On the other hand, when 
grown in form of static biofilms, the structural environment for this particular public good 
is not enough to favor cooperation,  and cheaters sensitive to antibiotics are able to 
progress and modify the structure of the biofilm, which becomes thinner and prone to 
antibiotic penetration, facilitating partial elimination of the community after antibacterial 
treatment (the remaining biofilm is around 80% when the cheater frequency = 0.5)  (117). 
Equally conflicting results have been obtained depending on the animal model. QS cheats 
seem to be able to dominate the population in vertebrate models (mouse) (118). whereas, 
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results on C. elegans indicate that the progression of cheaters within the population could 
be constrained due to the structured environment (119). 
 In vitro, in unstructured environments, competing pyoverdine cheaters are able to 
obtain a higher relative fitness than that of producer strains when iron is scarce, showing 
the potential to act as Trojan horses (25,33,63,120). Nevertheless, this seems to be context 
specific and the environment might play a big role (121).  As mentioned above, bacteria 
usually grow in form of biofilms and increasing the structure or reducing the diffusivity 
of the environment in vitro usually reduces the cheater relative fitness below that of the 
cooperators (33,122,123). Testing the pyoverdine system in animal models (C. elegans 
and G. mellonella), even with very low initial frequencies of cheaters, acting against 
competition, do not result in improved cheater relative fitness over cooperators, although 
they result in a decreased growth and virulence of the whole bacterial population 
(119,124), indicating that the structure of those populations might be playing a role in the 
colonisation of the animal models. 
These results indicate that although there is potential in these alternative strategies 
using the pyoverdine system, new approaches must be taken for generating a successful 
Trojan horse strain (total invasion). In this sense, the selection of public goods must be 
based on the requirements of each bacterium in the specific environment in which it is 
going to be introduced and the time-span of the experiment needs to be carefully 
considered. 
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Figure 1.5: Antibiotics versus social disruption. (A) Traditional antibiotic therapies 
favour emergence of resistance. (B) An approach based on social evolutionary theory can 
shift selection away from resistance facilitating immune clearance. Taken from (125). 
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1.8- Rationale for developing Trojan horses in the pyoverdine system 
 
This work aims to solve the problem of introducing specific phenotypes for 
community invasion under structured environments, in order to offer alternative 
treatments in line with DM. I focus on pyoverdine as the social trait exploited in this 
approach based on the detailed understanding of the basic biology and complex 
interactions driving social behaviours linked to this trait. The goal is to modify P. 
aeruginosa pyoverdine production, by the inactivation of either of the differentially 
regulated receptors, FpvA (partly coupled to pyoverdine synthesis) or FpvB (unknown 
down regulatory elements), which are also expected to exhibit different affinities and 
efficiencies in ferri-pyoverdine transport (Fig. 1.6). As a result of this approach I expect 
to obtain producer strains with altered optimal benefit-cost ratios. The fact that these 
strains will be producers, should allow them to grow in structured environments, where 
growth is limited for non-producers, independently on the diffusivity of the public good 
and in the absence of a wildtype producer strain. If one of the modified strains results in 
an optimized cost/benefit ratio, it should grow faster than the wildtype, thus dominating 
the population. Therefore, in order to overcome limitation of competitive strategies 
imposed by population structure, I suggest the use of optimized fitter cooperative strains 
rather than non-cooperative ones. 
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Figure 1.6: Rationale of the approach taken for developing Trojan horses in this 
PhD thesis. A: Binding of ferri-pyoverdine to FpvA yields a regulatory response 
involving sigma factors PvdS and FpvI, whereas no such regulatory circuits have been 
described for FpvB. B: In unstructured populations, the public good (green shades) is 
accessible to every member of the community and non-producers (blue) gain a selective 
advantage, which might lead to the collapse of the population. C: A traditional approach 
to modify populations using non-producer strains, which remain limited by distance and 
accessibility to public good synthesized by producer micro-colonies (P-green), renders 
cheats unable to dominate the population. D: The approach reported in this work, where 
optimized producer micro-colonies (P*) are able to grow faster without requiring the 
nearby presence of public goods generated by standard producers. 
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1.9- Aim and hypotheses 
 
As stated in the introduction, the main goal of this work is the development of 
microbial strains that could be used for the invasion of a wildtype population 
exploiting the evolutionary dynamics resulting from the exchange of cooperative 
traits. I studied the well stablished pyoverdine system of P. aeruginosa as a model for 
social microbial interactions and, unlike other works in this field, I focused on the receptor 
proteins for pyoverdine uptake in order to produce strains with altered balances of costs 
and benefits in iron limited conditions. This work is aimed at testing the following 
hypotheses related to the fundamental biology of pyoverdine in this organism:  
 
1- ΔfpvA and ΔfpvB have never been considered for competition studies. Despite 
the lack of information about the general behaviour of mutants in the secondary 
receptor the knowledge of the genetic circuitry of pyoverdine suggests that 
growth should be affected in different ways for each of the mutants. 
2- The artificial upregulation of the expression of receptors should yield more 
efficient strains requiring lower amounts of pyoverdine to sustain a better 
growth. 
3- Strains with optimised costs and benefits of pyoverdine synthesis and reception 
possess a fitness advantage and should become the dominant strains in a 
population when competing against a wildtype strain in homogeneous 
environments. 
4- Single mutants in each of the receptors should still be able to produce 
pyoverdine, thus leading to an advantage when grown in structured 
environments compared to pyoverdine canonical cheats. 
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2.1-Media and strains: 
 
LB media was prepared using 10 g/L peptone, 5 g/L yeast extract and 10 g/L NaCl. 
For agar plates, 15 g/L of agar (Oxoid, Basingstoke, UK) were added. Iron-limited 
casamino acid media (CAA) was prepared using 5 g vitamin free casamino acids (Sigma 
Aldrich, UK), 1.18 g K2HPO4.3H2O, 0.25 g MgSO47H2O (Oxoid, UK), per litre of dH2O, 
supplemented with 200 μg/mL of human apo-transferrin (Sigma Aldrich, UK), and 20 
mM sodium bicarbonate (Fisher Scientific, UK). CAA pH was adjusted to 7 and  buffered 
using 50mM HEPES. Apotransferrin is used to avoid iron sequestration by secondary 
chelators generated by P. aeruginosa, while sodium bicarbonate is required for its activity 
(21). Pseudomonas Isolation Agar plates were prepared following the manufacturer 
(Fisher Scientific, UK) instructions. 
Media were supplemented with 20 µg/mL of gentamycin, 30 µg/mL of 
chloramphenicol, 50 µg/mL of kanamycin and 150 µg/mL of ampicillin when required 
(all antibiotics were purchased from Sigma-Aldrich, UK). 
To supplement bacterial growth with pyoverdine, P. aeruginosa ΔpchE was grown 
in CAA for 48 hours and the supernatant was filter-sterilized three times. The use of this 
mutant avoided production of the secondary iron chelator, pyochelin. In the required 
condition, this supernatant was added (10% vol/vol) to fresh CAA.  
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Strain Description Source 
P. aeruginosa MPAO1 Parental strain/Wildtype (126) 
P. aeruginosa ΔpvdA  
Defective strain for pyoverdine synthesis. PW5012. P. 
aeruginosa gene no. PA2386, gene product: L-ornithine 
N5-oxygenase. Transposon ISlacZ/hah.  
(126) 
P. aeruginosa ΔfpvA  
Defective strain for pyoverdine primary receptor. PW5036. 
P. aeruginosa gene no. PA2398, gene product: FpvA 
pyoverdine receptor.Transposon ISlacZ/hah. 
(126) 
P. aeruginosa ΔfpvB  
Defective strain for pyoverdine secondary receptor. 
PW8065. P. aeruginosa gene no. PA4168, gene product: 
FpvB pyoverdine receptor.Transposon ISlacZ/hah. 
(126) 
P. aeruginosa ΔpchE 
Defective strain for pyochelin receptor. PW8174. P. 
aeruginosa gene no. PA4226, gene product: 
dihydroaeruginoic acid synthetase.Transposon ISpho/hah. 
(126) 
P. aeruginosa MPAO1::Tn7:acc3 
P. aeruginosa MPAO1 carrying acc3, conferring 
gentamicin resistance in the Tn7 location 
This study 
P. aeruginosa ΔpvdA::Tn7:acc3 
P. aeruginosa ΔpvdA carrying acc3, conferring gentamicin 
resistance in the Tn7 location 
This study 
P. aeruginosa ΔfpvA::Tn7:acc3 
P. aeruginosa ΔfpvA carrying acc3, conferring gentamicin 
resistance in the Tn7 location 
This study 
P. aeruginosa ΔfpvB::Tn7:acc3 
P. aeruginosa ΔfpvB carrying acc3, conferring gentamicin 
resistance in the Tn7 location 
This study 
P. aeruginosa 
MPAO1::Tn7:acc3:fpvAp:mCherry 
P. aeruginosa MPAO1 with genomic insertion of Tn7-
fpvAp-mCherry in the Tn7 location 
This study 
P. aeruginosa 
ΔpvdA::Tn7:acc3:fpvAp:mCherry 
P. aeruginosa ΔpvdA with genomic insertion of Tn7-
fpvAp-mCherry in the Tn7 location 
This study 
P. aeruginosa 
ΔfpvA::Tn7:acc3:fpvAp:mCherry 
P. aeruginosa ΔfpvA with genomic insertion of Tn7-fpvAp-
mCherry in the Tn7 location 
This study 
P. aeruginosa 
ΔfpvB::Tn7:acc3:fpvAp:mCherry 
P. aeruginosa MPAO1 with genomic insertion of Tn7-
fpvAp -mCherry in the Tn7 location 
This study 
P. aeruginosa 
MPAO1::Tn7:acc3:fpvBp:mCherry 
P. aeruginosa MPAO1 with genomic insertion of Tn7-
fpvBp-mCherry in the Tn7 location 
This study 
P. aeruginosa 
ΔpvdA::Tn7:acc3:fpvBp:mCherry 
P. aeruginosa ΔpvdA with genomic insertion of Tn7-fpvBp-
mCherry in the Tn7 location 
This study 
P. aeruginosa 
ΔfpvA::Tn7:acc3:fpvBp:mCherry 
P. aeruginosa ΔfpvA with genomic insertion of Tn7-fpvBp-
mCherry in the Tn7 location 
This study 
P. aeruginosa 
ΔfpvB::Tn7:acc3:fpvBp:mCherry 
P. aeruginosa ΔfpvB with genomic insertion of Tn7-fpvB -
mCherry in the Tn7 location 
This study 
P. aeruginosa 
MPAO1::Tn7:acc3:14FfpvB 
P. aeruginosa MPAO1 with genomic insertion of Tn7-
14FfpvB in the Tn7 location 
This study 
P. aeruginosa 
ΔfpvA::Tn7:acc3:14FfpvB 
P. aeruginosa ΔfpvA with genomic insertion of Tn7-
14FfpvB in the Tn7 location 
This study 
P. aeruginosa 
MPAO1::Tn7:acc3:GFP/RFP:14F 
P. aeruginosa MPAO1 with genomic insertion Tn7-
GFP/RPF-control14F in the Tn7 location 
This study 
P. aeruginosa 
ΔfpvA::Tn7:acc3:GFP/RFP:14F 
P. aeruginosa ΔfpvA with genomic insertion of Tn7-
GFP/RPF-control14F in the Tn7 location 
This study 
P. aeruginosa 
ΔfpvB::Tn7:acc3:GFP/RFP:14F 
P. aeruginosa ΔfpvB with genomic insertion of Tn7-
GFP/RPF-control14F in the Tn7 location 
This study 
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P. aeruginosa 
ΔpvdA::Tn7:acc3:GFP/RFP:14F 
P. aeruginosa ΔpvdA with genomic insertion of Tn7-
GFP/RPF-control14F in the Tn7 location 
This study 
P. aeruginosa 
ΔfpvA::Tn7:acc3:GFP/RFP:14FfpvB 
P. aeruginosa ΔfpvA with genomic insertion of Tn7-
GFP/RFP-14FfpvB in the Tn7 location 
This study 
E. coli DH5α 
Competent cells. Genotype:  F– endA1 glnV44 thi-1 recA1 
relA1 gyrA96 deoR nupG purB20 φ80dlacZΔM15 
Δ(lacZYA-argF)U169, hsdR17(rK–mK+), λ–. 
(127) 
One Shot™ PIR2 Chemically 
Competent E. coli 
Competent cells. Genotype F-∆lac169 rpoS(Am) robA1 
creC510 hsdR514 endA recA1 uidA(∆MluI)::pir. 
Thermofisher/Invitrogen 
Table 2.1: List of bacterial strains 
 
 
2.2-Growth curves, pyoverdine production and promoter expression 
measurement: 
 
Otherwise stated, the general protocol for growth curves is as follows. Cells were 
taken from single clone frozen stocks and grown overnight at 37°C 200 rpm in 5 mL LB 
supplemented with antibiotics if required. The following day, cells were transferred (1%) 
to fresh LB in standard 24 well plates and grown to mid-exponential phase (BMG-
Clariostar, 37°C, 500 rpm). Once cells reached mid-exponential phase, they were washed 
3 times in phosphate saline buffer (PBS), and OD600 normalized to 1 (Thermo Scientific 
Evolution 60S UV-Visible Spectrophotometer). Cells were then diluted to OD600 0.01 
in CAA (supplemented when required with pyoverdine and/or gentamicin) and grown in 
standard 96 well plates (BMG-Clariostar, 37°C, 500 rpm) measuring OD600, pyoverdine 
fluorescence at 450nm(Ex)/490nm(Em) and mCherry fluorescence (promoter expression) 
at 587nm(Ex)/610nm(Em) every 30 minutes. No fluorescence cross-talk was observed 
between wells. Working volumes for 24 and 96 well plates were 1 mL and 200 µL 
respectively in all the experiments.  Positions of strains on  well plates were randomized, 
and outer wells of plate were filled with blank medium to minimize problems due to 
evaporation.  
 
30 
 
2.3-General molecular techniques (PCR, Digestion/Ligation): 
 
DNA amplification was performed by PCR, using the Q5 DNA polymerase kit 
(New England Biolabs, USA) and the corresponding primers following the 
recommendations of the manufacturer. The PCR comprised an initial denaturation step 
(98°C) of 5 minutes, followed by at least 25 cycles including: 10 seconds denaturation 
step (98°C), 30 seconds annealing step (generally 60°C) and a variable extension time (30 
seconds/kb) at 72°C. A final five-minute extension time at 72°C was performed to ensure 
maximum efficiency. 
Otherwise stated, plasmid construction was carried out using standard digestion and 
ligation procedures.  The general protocol involved plasmid extraction using the Qiaprep 
spin mini-prep kit (Qiagen, UK). Plasmid amount was quantified using a NanoDrop 
(Thermofisher, UK). Digestion and ligation reagents were obtained from New England 
Biolabs. 1 µg of plasmid was mixed with 10 units of the corresponding restriction 
enzymes and the corresponding amount of 1X restriction buffer in final 50 µL volume. 
Reaction was incubated at least for one hour or overnight when possible at the 
recommended temperature. After digestion, samples were purified using the QIAquick 
PCR Purification Kit (Quiagen) and if band purification was required, QIAquick Gel 
Extraction Kit (Qiagen) was then used following the instructions of the manufacturer. 
The resulting plasmids were chemically transformed into One Shot™ PIR2 
Chemically Competent E. coli cells following the instructions of the manufacturer. After 
transformation, cells were resuspended in 1 mL of LB and grown for one hour (37°C, 200 
rpm) before plating on LB agar supplemented with the required antibiotics. 
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2.4-Tri-parental mating for Tn7 chromosomal integration: 
 
Plasmids are frequently used as tools to express genes of interest (e.g fluorescent 
proteins) and they require the use of selective markers, otherwise they are usually curated 
in short periods of time. In addition, they can to affect bacterial fitness when they are 
present in an elevated copy number.  
Transposable Tn7 elements are one of the best systems to deliver specific genes 
into bacterial chromosome given that they insert in single copy in an specific intergenic 
region, downstream glms gene, and have been tested with great success in P. aeruginosa  
(128). In addition, Tn7 elements are stable and remain integrated in the chromosome for 
up to 100 generations without the need of antibiotics (129). 
 
Donor (One Shot™ PIR2 E. coli -R6K plasmids-), recipient (P. aeruginosa strains) 
and helper strains (E. coli DH5α carrying pRK600 and pTns-1 plasmids) were grown 
overnight on in 5 mL of LB supplemented with the required antibiotics. The helper and 
donor strains were re-inoculated (1%) in 1 mL of fresh LB and grown until 0.4-0.5 OD at 
37°C. The recipient strains were re-inoculated (10%) in 1 mL of fresh LB and grown for 
the same amount of time than the helper and donor strains but at 42°C with no agitation. 
The cells were then washed twice with 1mL of LB  to remove antibiotics. 100 µL of each 
strain were mixed, centrifuged, re-suspended in 30 µL of LB and plated onto an antibiotic-
free LB agar plate. After 6 hours at 37°C, the cells were re-suspended from the plate in 1 
mL of LB. The cell pellet was recovered, resuspended in 30 µL of PBS and plated on 
Pseudomonas Isolation Agar with gentamycin to select for bacteria carrying the genetic 
construction.  Tn7 presence was confirmed by colony PCR, following the aforementioned 
32 
 
protocol, using both Tn7RFW and glmsDownREV primers (in the construction and in the 
upstream glms gene). 
 
2.5-fpvA and fpvB fluorescent reporter expression system construction: 
 
Initially, mCherry was cloned instead of msfGFP in pBG25, to avoid possible signal 
overlaps between pyoverdine and the fluorescent protein. To do so, mCherry was 
amplified using the mChFWeco and mChREVbam oligonucleotides containing 
EcoR1/BamH1 sites. The PCR product together with pBG25 were digested with 
EcoR1/BamH1 followed by ligation and transformation in One Shot™ PIR2 E. coli. The 
primers used to test whether the ligation process was successful were mChFWconf and 
mChREVconf. 
The resulting plasmid, pBG25-mCherry, contained the 14F promoter (a strong 
synthetically engineered promoter), a bicistronic linker carrying a secondary ribosome 
binding site (RBS) and mCherry.  
 In the next step, the promoter regions of fpvA and fpvB genes were cloned into 
pBG25-mCherry. The bicistronic linker carried by pBGXX plasmids was introduced to 
solve the problem of translational variability caused by mRNA secondary structure, thus 
making promoter activity comparable between genes by normalizing translation, 
(130,131). mRNA secondary structure in the region between -4 and +37 relative to the 
translation star site accounts for almost 60% of the protein expression variability (132). 
Indeed, the addition of a series of 28 codons with predicted low mRNA sequences after 
the translation start site produced constantly high expression of reporter genes (133). 
However, many proteins will not tolerate N-terminal fusions and to solve this, the 
bicistronic linker was designed. pBGXX plasmids contain a 5´UTR with two ribosome 
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binding sites: the first one initiates translation of a short peptide while the second one is 
integrated in the sequence of this short peptide and defines the strength of translation of 
the downstream gene of interest (130,131). This short peptide (with low mRNA 
secondary structure) contains a termination codon overlapped to the start codon of the 
gene of interest, so the ribosome does not detach from the mRNA when the short peptide 
translation is finished (131). By keeping this construction, it is possible to account for the 
majority of the expression variability considering only variation in the promoters and 
variation in the bicistronic linker (131). 
The fpvA promoter of P. aeruginosa MPAO1 was obtained as a pair of 
complementary oligonucleotides (fpvApFWpac and fpvApREVavr) containing the whole 
sequence and the restriction sites. The oligonucleotides were annealed using T4 DNA 
ligase buffer (1x;without the enzyme) heated to 95oC for five minutes in a water bath and 
allowed to cool down to room temperature. The fpvB promoter region of P. aeruginosa 
MPAO1 was PCR amplified using fpvBpFWpac and fpvBpREVavr primers. Both 
promoters (fpvA and fpvB) and pBG25-mCherry were digested using PacI /AvrII, ligated 
and transformed, resulting in pBG25-fpvAp-mCherry and pBG25-fpvBp-mCherry. The 
primers used to test whether the ligation process was successful were mChFWconf and 
mChREVconf. Constructions were then integrated into the Tn7 site of the different P. 
aeruginosa strains following the protocol already described. Confirmation of the correct 
insertion of the desired fragments was obtained through PCR using both Tn7RFW and 
glmsDownREV primers, followed by DNA Sanger sequencing (Genewiz, UK). 
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2.6-Construction of strains overexpressing FpvB secondary receptor: 
 
In order to obtain strains able to overexpress fpvB, the natural ribosome binding site 
and the gene fpvB from P. aeruginosa MPAO1 were PCR amplified with the 
corresponding restriction sites (XbaI/HindIII) added at the 5´ end of the primers 
fpvB+RBSFWxba and fpvB+RBSREVhind. pBG25 was digested using AvrII/HindIII 
(note that XbaI and AvrII present compatible ends). Both fragments, pBG25 backbone 
and the fpvB gene were then ligated and transformed into in One Shot™ PIR2 E. coli. 
The primers used to test whether the ligation process was successful were 
fpvB+RBSFWconf and fpvB+RBSREVconf. The plasmid generated, pBG25-14FfpvB, 
carried the construction that was integrated into the Tn7 locations of P. aeruginosa 
MPAO1 and P. aeruginosa ΔfpvA following the protocol already described, generating 
P. aeruginosa MPAO1::Tn7:acc3:14FfpvB and P. aeruginosa 
ΔfpvA::Tn7:acc3:14FfpvB. The correct modification of the strains was confirmed by 
PCR and Sanger sequencing (Genewiz, UK). 
2.7-Construction of fluorescently tagged strains for competition studies: 
 
In order to allow for proper comparisons between strains, all competition 
experiments were conducted with a modified version of the different mutants that 
reproduce the genetic architecture of the Tn7 insertion in the engineered P. aeruginosa 
ΔfpvA::Tn7:acc3:14FfpvB. Strains were constructed so they would share the same DNA 
insert with the exception of the fpvB gene. These strains were generated as follows: 
pBG25-mCherry was digested with AvrII/XbaI and religated, obtaining pBG25-
control14F. In addition, several of the competing strains were pyoverdine producers and 
they were tagged with fluorescent reporters to allow their differentiation.  
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Ptet for the constitutively expression of fluorescent tags and the corresponding 
terminators were amplified from MBP-1.0 and MBP-swap using two different sets of 
primers: GFP/RFPFW_MBPpac together with GFP/RFPREV_MBPxho  and 
GFP/RFPFW_MBPpac with GFP/RFPREV_MBPbam, containing PacI/XhoI and 
PacI/BamHI restriction sites respectively for each of the destination backbones. Equally, 
backbone plasmids were amplified using BG25_C14FFWpac with BG25_C14FREVxho 
and BG25_14FBFWpac with BG25_C14FBREVbam primers containing the 
corresponding specific restriction sites (PacI/XhoI and PacI/BamHI). Therefore, when 
cloning into pBG25-control14F, PacI/XhoI were used as restriction enzymes. When 
pBG25-14FfpvB was the recipient backbone, Pac/BamHI were used. The ligation of the 
corresponding fragments yielded 2 plasmids with alternate colours (4 in total): pBG25-
GFP/RPF-control14F and pBG25-GFP/RFP-14FfpvB (Appendix Figure 1). The primers 
used to test whether the ligation process was successful were BG25_TAGFW, 
BG25_TAG_GFPREV and BG25_TAG_RFPREV. The transposons carrying the 
required DNA inserts were delivered by triparental mating yielding: P. aeruginosa 
MPAO1::Tn7:acc3:GFP/RFP:14F, P. aeruginosa ΔfpvA::Tn7:acc3:GFP/RFP:14F, P. 
aeruginosa ΔfpvB::Tn7:acc3:GFP/RFP:14F, P. aeruginosa 
ΔpvdA::Tn7:acc3:GFP/RFP:14F, P. aeruginosa ΔfpvA::Tn7:acc3:GFP/RFP:14FfpvB. 
Insertions were confirmed by PCR and sequencing (Genewiz, UK). 
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Plasmid Description Source 
pRK600 Tra and Mob genes. Ori ColE1. CmR (130) 
pTn7-M 
ori R6K. Mobilizable Tn7 element with 
acc3 (gentamicin resistance). GmR KmR 
(130) 
pTns-1 
ori R6K, Transposase (TnSABC+D) 
operon. ApR 
(128) 
pBG25 
ori R6K. Mobilizable Tn7 element with 
acc3 (gentamicin resistance) and 
msfGFP, under the control of 14F 
promoter and a bicistronic linker. GmR 
KmR 
(130) 
pBG-control 
ori R6K. Mobilizable Tn7 element with 
acc3 (gentamicin resistance). GmR KmR 
This study 
pBG25-control14F 
ori R6K. Mobilizable Tn7 element with 
acc3 (gentamicin resistance) and an 
empty 14F promoter. GmR KmR 
This study 
pBG25-mCherry 
ori R6K. pBG25 carrying mCherry 
under the control of 14F promoter and a 
bicistronic linker. GmR KmR 
This study 
pBG25-fpvAp-mCherry 
ori R6K. pBG25-mCherry with fpvA 
promoter and a bicistronic linker. GmR 
KmR 
This study 
pBG25- fpvBp-mCherry 
ori R6K. pBG25-mCherry with fpvB 
promoter and a bicistronic linker. GmR 
KmR 
This study 
pBG25-14FfpvB 
ori R6K. pBG25 with fpvB gene. GmR 
KmR 
This study 
MBP-1.0 
Ori ColE2. GFPmut3b under the control 
of constitutive Ptet. 
(134) 
MBP-swapped 
Ori ColE2. mRFP1 under the control of 
constitutive Ptet. 
(134) 
pBG25-GFP/RPF-control14F 
ori R6K. pBG-control14F with Ptet 
regulated GFP/RFP expression. GmR 
KmR 
This study 
pBG25-GFP/RFP-14FfpvB 
ori R6K. pBG25-14FfpvB with Ptet 
regulated GFP/RFP expression. GmR 
KmR 
This study 
Table 2.2: List of plasmids 
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 Figure 2: Cloning strategy diagram 
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Name Use // Restriction enzymes Sequence 5´-3´ 
mChFWeco 
mChREVbam 
Cloning mCherry into pBG25 // 
EcoR1/BamH1 
FW:tgggaattcttAGCAAGGGCGAGGAGGATA 
REV:agaggatccTTACTTGTACAGCTCGTCCATGCC
GC 
fpvApFWpac 
fpvApREVavr 
Cloning fpvA promoter into pBG25-
mCherry  // PacI/AvrII 
FW:gtcttaattaaAACTTTTTCATCCGGTTTTCCGTG
GGTAAAACGTCATACTAAGAGAATTGAGAAGC
GATCTCATTTATTCGCAACTTGCCAACCTcctagg
gcc 
REV:ggccctaggAGGTTGGCAAGTTGCGAATAAAT
GAGATCGCTTCTCAATTCTCTTAGTATGACGTT
TTACCCACGGAAAACCGGATGAAAAAGTTttaatt
aagac 
fpvBpFWpac 
fpvBpREVavr 
Cloning fpvB promoter into pBG25-
mCherry // PacI/AvrII 
FW:actttaattaaGGCTGCGCTCCGTGGGCGGGAT 
REV: aatcctaggGCGGCGCAGGCAGGCCGTT 
mChFWconf 
mChREVconf 
Cloning confirmation primers for 
pBG25-mCherry, pBG25-fpvAp-
mCherry and pBG25-fpvBp-mCherry 
FW:cgacctagggcccaagttcac 
REV:ATGTTGACGTTGTAGGCGCCGG 
fpvB+RBSFWxba 
fpvB+RBSREVhind 
Cloning fpvB with its natural 
ribosome into pBG25 // AvrII-
Xba/HindIII 
FW:cgctctagaGCCATCCAGGACACTGCAGATG 
REV:gcgaagcttTCAGAGCGAGTACTTCACCGTG 
fpvB+RBSFWconf 
fpvB+RBSREVconf 
Cloning confirmation primers for 
pBG25-14FfpvB 
FW:ttacgaaccgaacaggctt 
REV:cgccagggttttcccagtcacgac 
GFP/RFPFW_MBPpac 
GFP/RFPREV_MBPxho 
Cloning of Ptet-GFP/RFP from MBP-
1.0/ MBP-swap into pBG25-
control14F // PacI/XhoI 
FW:cacttaattaatccctatcagtgatagagattgacatccc 
REV:ctactcgagaacgcgaagtaatcttttcggttttaaag 
GFP/RFPFW_MBPpac 
GFP/RFPREV_MBPbam 
Cloning of Ptet-GFP/RFP from MBP-
1.0/ MBP-swap into pBG25-14FfpvB 
// Pac/BamHI 
FW:cacttaattaatccctatcagtgatagagattgacatccc 
REV:cgtggatccaacgcgaagtaatcttttcggttttaaag 
BG25_C14FFWpac 
BG25_C14FREVxho 
pBG25-control14F backbone 
amplification to host Ptet-GFP/RFP 
from MBP-1.0/ MBP-swap // 
PacI/XhoI 
FW:cacttaattaagcccgttgacatgacatggtt  
REV:ctatctcgaggacgtcttgacataagcctgttcgg 
BG25_14FBFWpac 
BG25_C14FBREVbam 
pBG25-14FfpvB backbone 
amplification to host Ptet-GFP/RFP 
from MBP-1.0/ MBP-swap // 
Pac/BamHI 
FW:cacttaattaagcccgttgacatgacatggtt 
REV:tatggatccgacgtcttgacataagcctgttcgg 
BG25_TAGFW 
BG25_TAG_GFPREV 
BG25_TAG_RFPREV 
Cloning confirmation primers for 
plasmids carrying Ptet-GFP/RFP from 
MBP-1.0/ MBP-swap 
FW:tttacgaaccgaacaggctt 
REV(GFP):ACGGGAACTACAAGACACGTG 
REV(RFP):CTGCGTGGTACCAACTTCCC 
Tn7RFW 
glmsDownREV 
Confirmation of Tn7 element 
integration 
FW:cacagcataactggactgatttc 
REV gcacatcggcgacgtgctctc 
Table 2.3: List of primers. Bold regions indicate restriction sites for enzymatic digestion. 
Lower case indicates intergenic regions. 
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2.8-Competition experiments in the flow cytometer (unstructured 
environment): 
 
Cells were taken from single clone frozen stocks and grown overnight at 37°C 200 
rpm in 3 mL of LB supplemented with antibiotics if required. The following day, cells 
were transferred (1%) to fresh LB  in standard 24 well plates and grown to mid-
exponential phase (BMG-Clariostar, 37°C, 500 rpm). Once the cells reached the mid-
exponential phase, they were washed 3 times in 1 mL of PBS, and their OD600 was 
normalized to 1 (Thermo Scientific Evolution 60S UV-Visible Spectrophotometer). The 
cells were then diluted to OD600 0.01 in 3 mL of CAA with and without gentamicin 
supplementation in a 50 mL falcon tube and grown at 37°C, 200 rpm for 48 h. Samples 
were taken at 0, 18, 24 and 48 h and diluted in PBS prior to fluorescence-activated cell 
sorting (FACS). Samples were analysed using a Attune NxT cytometer, counting at least 
10,000 single events per sample. Data analysis was performed using FlowJo V10 (BD 
Biosciences, Europe).  
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Representative FACS workflow: 
Figure 2.1: representative FACS workflow 
 
(A) To gate the population of interest (POI / singlets), events were represented on a 
SSC-A vs SSC-H scatter plot. The same singlets gate was preserved in all the 
samples during the different biological replicates of the competition studies. 
(B) POI representing (in this example) 86.2% of the total number of events in A. 
(C) GFP+ (Q1) and RFP+ (Q3) populations and their corresponding frequencies 
within the singlet gated POI.  
*Fluorescence controls are shown in Appendix Figure 2 
Table 2.4: Attune NxT parameter configuration 
Parameter Voltage Logic gate / Threshold 
FSC 720 AND / 10 x 1000 
SSC 420 AND / 1 x 1000 
BL1 Ex:488 nm Em:530/30 
nm 
620 - 
YL2 Ex:561 nm Em:620/15 
nm 
800 - 
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To confirm the validity of the experiments, samples from the competition between 
MPAO1::Tn7:acc3:GFP/RFP:14F and ΔfpvA::Tn7:acc3:GFP/RFP:14FfpvB were diluted 
and  plated at times 0, 18 and 24 h on Pseudomonas isolation agar supplemented with 
gentamicin. 
2.9-Competition experiments in the confocal microscope (structured 
environment): 
 
Cells were taken from single clone frozen stocks and grown overnight at 37°C 200 
rpm in 3 mL LB supplemented with antibiotics if required. The following day, cells were 
transferred (1%) to fresh LB  in standard 24 well plates and grown to mid-exponential 
phase (BMG-Clariostar, 37°C, 500 rpm). Once the cells reached mid-exponential phase, 
they were washed 3 times in 1 mL of PBS, and the OD600 normalized to 1 (Thermo 
Scientific Evolution 60S UV-Visible Spectrophotometer). Cells were then diluted to 
OD600 0.01 in CAA with and without gentamicin supplementation and 30 µL were 
inoculated in a µ-Slide VI – Flat (Ibidi, Germany) and incubated at 37°C in a humid 
chamber with no agitation for 48 hours. The slides were inspected under the confocal 
microscope (Nikon A1M). Confocal images were acquired using identical gain, offset 
and pinhole settings for each data collection point. A single argon laser line was used with 
excitation wave-length of 488 nm and using an emission Nikon-FITC filter (525/50 nm) 
for the imaging of GFP-tagged bacteria;for RFP cells the excitation wavelength used was 
561 nm with the Nikon-mCherry (595/50 nm) emission filter. Images were collected from 
10 random areas with a 60x Plan Apo lens. 
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2.10-Monoinfections and competition experiments in Galleria mellonella: 
 
Galleria mellonella were acquired from a local supplier. Larvae were stored at 4°C 
and discarded if the age was over two weeks. Cells were taken from single clone frozen 
stocks and grown overnight at 37°C 200 rpm in 3 mL of LB supplemented with antibiotics 
if required. The following day, cells were transferred (1%) to fresh LB  in standard 24 
well plates and grown to mid-exponential phase. Once cells reached mid-exponential 
phase, they were washed 3 times in PBS, and the OD600 was normalized to 1 (Thermo 
Scientific Evolution 60S UV-Visible Spectrophotometer). Prior to infection, larvae were 
kept in ice for half an hour to prevent spontaneous movements. Then, larvae were dipped 
in 70% ethanol to remove any contaminants present on the tegument prior to injection. 
Cells were further diluted so that a 10 µL injection in G. mellonella would contain bacteria 
in the range of 102-103 cells. Following this, a stock solution of gentamicin was diluted 
accordingly in PBS to obtain a 20 µg/mL final concentration in the larvae after a 10 µL 
injection, assuming that every larvae as a volume of 1 mL. Both bacteria and gentamicin 
were injected in the las pair of prolegs using a Hamilton syringe and a peristaltic pump. 
Syringes were discarded after each treatment to prevent carryover between samples. 
Larvae were incubated at 37°C and their survival was checked every hour for mono-
infections. Larvae were considered dead if there was no sudden movement after touch 
with a pipette tip on the head. For competition experiments, cells were mixed in a 0.5:0.5 
(MPAO1:mutant) prior to injection, followed by antibiotic administration also by 
injection. Larvae were culled at 15 hours with the haemocoel being recovered. To do so, 
larvae were kept in ice for 30 minutes until no movement was detected, then a small 
incision was generated using a sterile scalpel. The scalpel was sterilized in ethanol after 
each cut to prevent carry over between samples. The haemocoel was recovered, diluted 
and 20 µL were plated on Pseudomonas Isolation Agar supplemented with gentamicin to 
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calculate population proportions. Cells were allowed to grow for 18 hours at 37°C and 
then stored for 3 days at 4°C, which facilitates their differentiation through fluorescent 
reporter accumulation in the bacterial colonies. 
2.11-Data analyses: 
 
All graphs were plotted using ggplot2 (R package). OD was fitted using Fitderiv 
(135) in order to obtain derivative curves accounting for growth rates at each time point. 
Pyoverdine production per cell was calculated as the fluorescence at 450 nm(Ex)/490 
nm(Em) divided by OD600 at each time point. The area under the curve (AUC) of 
pyoverdine production up to the maximum growth rate was obtained using the OD600 
derivative curve calculated with Fitderiv as an indicator of the point of maximum growth 
rate. The calculations of AUC were performed using Graphpad Prism 7.  
For the analysis of growth curves and promoter expression, acting the wildtype 
strain of each condition as the corresponding control, T-test and ANOVA complemented 
with Dunnett post-hoc tests, were performed using GraphPad Prism 7. When receptors 
were overexpressed, the corresponding control strain for each condition was the strain 
carrying an empty construction. For competition experiments under unstructured and 
semi-structured environments, the control condition involved the competition between 
MPAO1 and ∆pvda (non-producer strain) in the absence of gentamicin. For semi-
structured environments (biofilms), pixel frequency was calculated using Colour Pixel 
Counter plugin for ImageJ. During mono-infections and competitions in G. mellonella, 
the control condition was that without gentamicin. In all cases, the level of significance 
was established at p = 0.05. The survival curve analyses were performed using Long-
Rank test from survminer, an R package.  
44 
 
Chapter IIIa: Characterization of costs 
and benefits of pyoverdine synthesis in 
monocultures. Role of receptors. Results. 
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3.1-Initial characterization of the strains in CAA: growth, growth rates and 
pyoverdine production 
Growth and pyoverdine production dynamics, together with maximum growth 
rates, were inspected in monocultures of all the strains cultured on iron limited CAA with 
and without pyoverdine supplementation as described in section 2.1. 
  As depicted in Fig. 3.1, the ΔpvdA mutant strain showed lower growth when 
compared to the producer strains MPAO1, ΔfpvA and ΔfpvB. The ΔfpvA mutant showed 
an intermediate growth capacity, between the non-producer strain and the remaining 
pyoverdine producer strains (MPAO1 and ΔfpvB).  These two followed similar growth 
patterns up to seven hours, when MPAO1 growth was arrested. The addition of 10% 
(vol/vol) of spent medium containing pyoverdine led to an improved growth in all the 
strains. Under these conditions, ΔfpvA presented the lowest growth capacity, whereas 
ΔpvdA reached the highest OD600 values (> 1). 
Analysis of growth rates (Fig. 3.3) without pyoverdine supplementation (One-way 
ANOVA (F (3,8) = 298, p < 0.0001)), indicated that the maximum growth rate achieved 
by the ΔpvdA mutant (0.026 ± 0.001h-1) is lower than those showed by its producer 
counterparts, which range from 0.0505 ± 0.0013 to 0.0578 ± 0.0126 (h-1). A Dunnett 
multiple comparison test indicated significant differences in maximum growth rates 
between ΔfpvB and MPAO1 (p = 0.02) and between ΔpvdA and MPAO1 (p < 0.0001).  
As depicted in Fig. 3.2, ΔfpvA required a longer time to reach its maximum growth rate 
(over 10 hours), compared with MPAO1 and ΔfpvB (4.5 and 6.5 hours respectively).  
Supplementation with pyoverdine generated an increase in the maximum growth 
rate for all the strains (Fig 3.2). MPAO1, ΔfpvB and ΔpvdA maximum growth rates, were 
reached around 4 hours after the beginning of the experiment and ranged between 0.181 
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± 0.002 and 0.192 ± 0.012 (h-1). ΔfpvA, on the other hand, presented a slower growth, 
with a maximum growth rate value of 0.121 ± 0.00176 (h-1), which was reached after 6 
hours. One-way ANOVA (F (3,8) = 87.09, p < 0.001) and Dunnett multiple comparison 
test indicated significant differences in maximum growth rates between ΔfpvA and 
MPAO1 (p < 0.001). 
Regarding pyoverdine production (Fig. 3.4), in the absence of exogenous 
pyoverdine supplementation, the strains exhibited different dynamics. While MPAO1 and 
ΔfpvB presented a continuous increase in production, leading to the highest production 
per unit of OD, the ΔfpvA mutant produced a steady state during the second half of the 
exponential phase, yielding lower values when compared to the other two producer 
strains. ΔpvdA did not show any fluorescence during the experiment. When the medium 
was supplemented with exogenous pyoverdine, all producer strains followed a similar 
pattern, in which initially no pyoverdine was produced, up to a time point (4 hours), when 
de novo synthesis of pyoverdine began. Again, ΔpvdA was unable to yield any fluorescent 
signal during the experiment. 
As shown in Fig. 3.5, differential pyoverdine production levels are obtained when 
measured as the total fluorescence accumulated up to the point of maximum growth rate, 
being the ΔfpvA mutant the strain with the highest production, followed by ΔfpvB, 
MPAO1 and the non-producer strain ΔpvdA. When the mutant strains were compared to 
MPAO1, the ANOVA (F (3,8) = 4481, p < 0.001) and Dunnett tests returned significant 
differences for all the comparisons (p < 0.001). On the other hand, none of the strains 
required the production of pyoverdine to reach their maximum growth rate in the presence 
of exogenous pyoverdine.  
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Figures 3.1, 3.2 and 3.3: Analysis of bacterial growth in CAA with and without 
pyoverdine supplementation: Bacteria were transferred to fresh CAA from mid-exponential 
phase in LB and grown at 37°C and 500 rpm for 20 hours. OD600 was measured every 30 minutes. 
OD600 and growth rate curves were respectively fitted and generated using Fitderiv. Error bars 
represent standard error of the mean from three biological replicates. 
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Figures 3.4, and 3.5: Analysis of pyoverdine production in CAA with and without 
pyoverdine supplementation: Bacteria were transferred to fresh CAA from mid-exponential 
phase in LB and grown at 37°C and 500 rpm for 20 hours. OD600 and fluorescence were measured 
every 30 minutes to obtain pyoverdine production per cell per time point. Pyoverdine production 
per cell up to the maximum growth rate was obtained calculating the area under the curve (AUC) 
up to the corresponding time point. Error bars represent standard error of the mean from three 
biological replicates. 
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These results describe for the first time the growth and pyoverdine production 
dynamics of the mutant ΔfpvB in iron limited CAA, which turned out to be close to those 
from MPAO1. In addition, they complete the existing information about ΔfpvA in terms 
of growth and pyoverdine production, confirming the ability of this strain to inefficiently 
grow in iron limited CAA due to, probably, the less efficient performance of FpvB 
compared to FpvA. 
3.2- Effect of gentamicin supplementation on growth, growth rates and 
pyoverdine production 
The next step was to analyze the effect of an environmental stressor (in this case 20 
µg/ul gentamicin) in the behaviour of the pyoverdine producer strains (MPAO1, ΔfpvA 
and ΔfpvB), were modified to carry a single copy of acc3 (conferring gentamicin 
resistance;see materials and methods) in the Tn7 location, downstream glms gene. In this 
section, for convenience, strains carrying the gentamicin resistance will be named by their 
mutations, except when compared with a non-gentamicin resistant, in which case, a 
distinction will be made. 
 Gentamicin has been reported to alter the dynamics of competition studies between 
antibiotic sensitive PAO1 and ΔpvdA (pyoverdine producer and non-producer and 
sensitive to the antibiotic) when using sublethal concentrations (136). In this work, 
resistant strains were generated to test whether dynamics are equally affected, which 
might be important in a clinical context. Therefore, gentamicin was used at even higher 
concentrations. Experimental conditions remained similar to those in the previous section, 
with the exception of the addition of 20 µg/mL gentamicin and the duration of the 
experiment (48 hours). 
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First, the influence of the construction carrying the gentamicin resistance gene was 
tested. For that, MPAO1 and MPAO1:: Tn7 : acc3 (resistant to gentamicin) were grown 
in iron limited CAA in the presence or absence of the antibiotic. Figs. 3.6, 3.7 and 3.8 
show how gentamicin resistance cassette (acc3) had no influence on the behaviour of the 
MPAO1 : Tn7 : acc3 strain growth, the growth rates or the pyoverdine production per 
cell per timepoint when compared to MPAO1 in the absence of gentamicin. In the 
presence of 20 µg/mL gentamicin, MPAO1 was unable to grow or produce pyoverdine 
whereas MPAO1:: Tn7 : acc3 had its growth affected. 
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Figures 3.6, 3.7 and 3.8: Analysis of bacterial growth in iron limited CAA in the 
presence or absence of 20 µg/mL of gentamicin (control): Bacteria were transferred to 
fresh CAA from mid-exponential phase in LB and grown at 37°C and 500 rpm for 48 hours. 
OD600 and fluorescence were measured every 30 minutes. OD600 and growth rate curves were 
respectively fitted and generated using Fitderiv. Error bars represent standard error of the mean 
from three biological replicates. 
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As shown in Fig. 3.9, growth in iron limited CAA with and without exogenous 
pyoverdine supplementation is affected by the presence of gentamicin. Again, for 
convenience, strains carrying the gentamicin resistance will be named by their mutations, 
except when compared with a non-gentamicin resistant, in which case, a distinction will 
be made. 
 The three strains presented longer lags, leading to an altered growth order with 
ΔfpvB showing the best growth capacity, followed by ΔfpvA and MPAO1, when 
compared to those in the absence of gentamicin (see previous section). Addition of 10% 
(vol/vol) of spent medium containing pyoverdine led to an improved growth and lag phase 
reduction in all the strains, yet, the altered order of growth was still maintained. ΔfpvA 
became the strain with the highest OD600 values at the end of the experiment in both 
conditions. 
 In the absence of exogenous pyoverdine, maximum growth rates correlate with the 
order of growth: 0.038 ± 0.0016 (ΔfpvB), 0.032 ± 0.001 (ΔfpvA) and 0.022 ± 0.001 
(MPAO1) h-1 (Fig. 3.11). Statistical analysis (One-way ANOVA (F (2,6) = 42, p = 
0.0002)) revealed significant differences in the maximum growth rates between MPAO1 
and ΔfpvA (p = 0.0012) and MPAO1 and ΔfpvB (p = 0.0002). Reaching the maximum 
growth rate required different amounts of time for each of the strains:  ΔfpvB required of 
14.5 hours, ΔfpvA needed 20.5 hours and over 22 hours were required for MPAO1 (Fig. 
3.10). 
Supplementation with pyoverdine generated an increase in the maximum growth 
rate for all the strains: 0.145 ± 0.003 for ΔfpvB, 0.109 ± 0.0022 for ΔfpvA and 0.12 ± 
0.004 for MPAO1 (h-1) (Fig. 3.10), which do not correlate with the order of growth (Fig 
3.9). In this condition, statistical analysis (One-way ANOVA (F (2,6) = 33.62, p = 
0.0005)) revealed significant differences in the maximum growth rates only between 
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MPAO1 and ΔfpvB (Dunnett, p = 0.0023) (Fig. 3.11). Maximum growth rate was 
observed at different culture times: 7.5 hours for ΔfpvB, 11 hours for ΔfpvA and 15.5 
hours for MPAO1 (Fig. 3.10). 
The investment in pyoverdine production per cell over time (Fig. 3.12) was 
increased in all the strains and both conditions, compared to the condition without 
gentamicin (see previous section), being MPAO1 the strain with the highest production, 
followed by ΔfpvB and ΔfpvA. While MPAO1 and ΔfpvB presented a continuous increase 
in production, ΔfpvA reached a steady state of production during mid-exponential phase, 
yielding lower values when compared to the other two producer strains. When the 
medium was supplemented with exogenous pyoverdine, MPAO1 and ΔfpvB followed a 
similar pattern although displaced in time, in which initially, no pyoverdine is produced, 
up to a point in mid exponential phase, when de novo synthesis of pyoverdine started and 
continued until stationary phase. ΔfpvA presented an initial steady state of production, up 
to 10 hours, when an increased in production was detected up to stationary phase. 
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Figures 3.9, 3.10 and 3.11: Analysis of bacterial growth in iron limited CAA with 
and without pyoverdine supplementation in the presence of 20 µg/mL of gentamicin: 
Bacteria were transferred to fresh CAA from mid-exponential phase in LB and grown at 37°C and 
500 rpm for 20 hours. OD600 was measured every 30 minutes. OD600 and growth rate curves 
were respectively fitted and generated using Fitderiv. Error bars represent standard error of the 
mean from three biological replicates. 
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Figures 3.12, and 3.13: Analysis of pyoverdine production in iron limited CAA with 
and without pyoverdine supplementation in the presence of 20 µg/mL of gentamicin: 
Bacteria were transferred to fresh CAA from mid-exponential phase in LB and grown at 37°C and 
500 rpm for 20 hours. OD600 and fluorescence were measured every 30 minutes to obtain 
pyoverdine production per cell per time point. Pyoverdine production per cell up to maximum 
growth rate was obtained calculating the area under the curve (AUC) up to that time point. Error 
bars represent standard error of the mean from three biological replicates. 
56 
 
As shown in Fig. 3.13, different pyoverdine production yields are obtained when 
measured as the AUC up to the point of maximum growth rate, being ΔfpvA mutant the 
strain with the highest production, followed by MPAO1 and ΔfpvB when no pyoverdine 
supplementation exists. When the mutant strains were compared with MPAO1 (One-way 
ANOVA (F (2,6) = 142.3, p < 0.0001)), Dunnett test returned significant differences 
between MPAO1 and ΔfpvA (p = 0.0001) and MPAO1 and ΔfpvB (p = 0.0075). The 
supplementation with pyoverdine was not enough to account for ΔfpvA reaching its 
maximum growth rate (contrary to MPAO1 and ΔfpvB), therefore requiring the synthesis 
of a small amounts of pyoverdine. Statistical analysis (One-way ANOVA (F (2,6) = 
101.5, p < 0.0001)) revealed significant differences in the maximum growth rates between 
MPAO1 and ΔfpvA (p = 0.0001). 
In order to explain the unequal response of the strains to the presence of gentamicin, 
the ratio of pyoverdine production required to reach the maximum growth rate in the 
absence of exogenous pyoverdine supplementation for both conditions (with and without 
gentamicin) was calculated. As seen in Fig. 3.14, the MPAO1 strain required 30 ± 2.7 
times more production of pyoverdine (as AUC ratio values) to reach its maximum growth 
rate when gentamicin was present. On the other hand, ΔfpvA and ΔfpvB required only 2.4 
± 0.004 and 2.58 ± 0.17 times more of pyoverdine. As expected, the statistical analysis 
(One-way ANOVA (F (2,6) = 103.4, p < 0.0001)) returned significant differences when 
comparing MPAO1 to ΔfpvA and ΔfpvB (p = 0.0001 for both cases). 
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Figure 3.14: Analysis of the influence of gentamicin (20 µg/mL) on pyoverdine 
production in iron limited CAA without pyoverdine supplementation: AUC for 
pyoverdine production were calculated from the plots depicting pyoverdine production per cell 
per timepoint for each condition. Error bars, corrected for error propagation, represent the 
standard error of the mean from three biological replicates. 
 
3.3-Expression dynamics of pyoverdine primary (FpvA) and secondary 
(FpvB) receptors. Exploitation as tools to alter growth and pyoverdine 
production dynamics 
 
As mentioned in the introduction, great attention has been paid to pyoverdine 
synthesis and its cost.  Nevertheless, P. aeruginosa has two pyoverdine receptors (FpvA 
and FpvB) for which there is a lack of information on their role as benefit carriers, the 
potential effect on their expression dynamics when one of them is missing and their 
impact on the evolution of the community, especially in the presence of an environmental 
stressor.  
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3.3.1-Inspection of the expression of pyoverdine receptors using fluorescent 
reporters (transcriptional fusions) 
 
In an initial experiment I monitored the expression dynamics of the pyoverdine 
receptors using transcriptional fusions in which the corresponding promoters were cloned 
in a Tn7 transposon for chromosomal delivery right upstream of a promoterless mCherry 
gene with a synthetic RBS (130). The cassette also contains a gentamicin resistance gene 
(acc3) as a selectable marker, allowing the study of a possible role of the antibiotic on 
receptor expression. Both constructions were independently integrated in single copy in 
the Tn7 site of the strains MPAO1, ΔfpvA and ΔfpvB. It is worth noting that this method 
allows for the monitoring of gene expression levels even in mutants unable to express the 
genes under study. In this section, for convenience, strains carrying the gentamicin 
resistance and the transcriptional fusions will be named by their mutations. 
Unexpected results (Fig. 3.15) were observed for the fpvA transcriptional signal in 
the absence of gentamicin: MPAO1 yielded the lowest values, despite having both 
receptors, followed by ΔfpvB and ΔfpvA, which produced the highest signal. When 
comparing ΔfpvA and ΔfpvB with MPAO1 (One-way ANOVA F = 96,69 p < 0.0001), 
significant differences were found (p = 0.0001 and p = 0.0034 respectively).  When 
gentamicin was added to the system, the transcriptional levels of fpvA were increased, 
showing MPAO1 the highest expression levels, followed by ΔfpvB and ΔfpvA in very 
close proximity. Again, when comparing ΔfpvA and ΔfpvB with MPAO1 (One-way 
ANOVA F = 64.09 p < 0.0001), significant differences were found (p = 0.0001 for both 
comparisons). 
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In the absence of gentamicin, the transcriptional activity of fpvB followed the same 
dynamics as those of fpvA. Therefore, MPAO1 exhibited the lowest values, despite 
having both receptors, followed by ΔfpvB and ΔfpvA, which yielded the highest signal. 
The comparative analysis of ΔfpvA and ΔfpvB with the MPAO1 strain (One-way ANOVA 
F = 1044 p < 0.0001), identified significant differences (p = 0.0001 and p = 0.0131 
respectively).  When gentamicin was added to the system, the mutant ΔfpvA increased the 
transcription of fpvB, becoming the highest one, followed by MPAO1 and ΔfpvB. Again, 
when comparing ΔfpvA and ΔfpvB with MPAO1 (One-way ANOVA F = 64.09 p < 
0.0001), significant differences were found (p = 0.0001 and p = 0.0043 respectively). 
In order to determine the actual relevance of gentamicin on the expression of the 
receptors for each of the strains, the ratios between the AUC determined in both 
conditions (presence and absence of gentamicin) was calculated for both the fpvA and 
fpvB transcriptional activity. As seen in Fig. 3.16, the fpvA transcriptional activity was 
increased 95.12 ± 35.34 times in the MPAO1 strain, 5.48 ± 0.6 times in ΔfpvB and 2.24 
± 0.17 times in ΔfpvA. These results lead to significant differences (One-way ANOVA F 
(2,6) = 6.67 p = 0.03) between MPAO1 and both ΔfpvA and ΔfpvB (p = 0.032 and p = 
0.036 respectively). On the other hand, the fold change of the fpvB transcriptional activity 
(Fig. 3.17) was in general lower, although still increases with gentamicin in MPAO1 
(10.43 ± 2.48 times). For ΔfpvA, the expression remained on the same log scale (2.05 ± 
0.08 times) whereas a small reduction was detected for ΔfpvB (0.86 ± 0.19 times). In this 
case, the statistical analysis (One-way ANOVA F = 13.18 p = 0.0064) indicated 
differences between the means, and a post-hoc Dunnett multiple comparison test revealed 
a significant difference between MPAO1 with ΔfpvA (p = 0.01) and with ΔfpvB (p = 
0.0059). 
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Figure 3.15: Analysis of the transcriptional levels of fpvA and fpvB up to the point 
of maximum growth rate in iron limited CAA: Bacteria were transferred to fresh CAA 
from mid-exponential phase in LB and grown at 37°C and 500 rpm for 20 hours. OD600 and 
fluorescence were measured every 30 minutes to obtain mCherry expression per cell per time 
point. mCherry production per cell up to maximum growth rate was obtained calculating the area 
under the curve (AUC) up to that time point. Error bars represent standard error of the mean from 
three biological replicates.  
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Figures 3.16: Analysis of the influence of gentamicin (20 µg/mL) on pyoverdine 
receptors expression in iron limited CAA without pyoverdine supplementation: OD 
and fluorescence were measured every 30 minutes to obtain mCherry expression per cell per time 
point. mCherry production per cell up to the maximum growth rate was obtained calculating the 
areas under the curve (AUC) up to that time point in the presence and absence of gentamicin. 
Error bars, corrected for error propagation, represent standard error of the mean from three 
biological replicates. The top left panel of 3.16 zooms in the right panel in order to show fpvA 
transcriptional values for the ΔfpvA and ΔfpvB mutants. Horizontal line is plotted on y=1, 
indicating no changes in ratios. Note differences in scale in y axis. 
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These results highlight the different dynamics of pyoverdine receptor expression in 
the presence or absence of environmental stressors. Regulatory events allowed the mutant 
strains to compensate for the lack of the other type of receptors and led to overexpression 
of specific receptors for each of the strains in the presence of gentamicin.  
3.3.2-Impact of altered pyoverdine secondary receptor (FpvB) expression on 
growth and pyoverdine production  
 
My previous results suggest that ΔfpvA is able to produce high amounts of 
pyoverdine and compensate the lack of primary receptor with the expression of the 
secondary receptor FpvB. Nevertheless, there is still a delay in ΔfpvA growth even under 
pyoverdine supplementation (Figs. 3.1 and 3.9), that could potentially be explained by 
insufficient  FpvB expression or by a lower efficiency in pyoverdine uptake displayed by 
this receptor.  
Therefore, overexpression of FpvB was considered as a potential candidate to alter 
growth dynamics of the ΔfpvA strain. As such, a recombinant genetic construct of fpvB 
was introduced as an extra copy in the genome. In this cassette fpvB is under the regulation 
of the strong constitutive promoter 14F (130). As in previous constructions, the selectable 
marker acc3 was added to the construction, allowing to study bacterial behaviour also in 
the presence of gentamicin. 
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3.3.2.1- Consequences of the alteration of the expression of the secondary 
pyoverdine receptor (FpvB) in the absence of gentamicin 
 
The inspection of bacterial growth revealed that there were no alterations in the 
growth of the MPAO1 strains (the control and the strain overexpressing FpvB) (Fig. 3.17) 
or their maximum growth rate (Fig. 3.19), either in the absence (t=1.617, df=4, p = 0.181) 
or presence (t=0.4543, df=4, p = 0.67) of exogenous pyoverdine. On the other hand, 
overexpression of FpvB in a ΔfpvA strain yielded a distinguishable advantage, 
particularly in the presence of exogenous pyoverdine, where the maximum growth rate 
was higher (0.16 ± 0.002 h-1-Fig 3.19-) and was reached earlier (5 hours -Fig 3.18-), 
which translates in a growth advantage. Therefore, significant differences in maximum 
growth rates were found in this case (t=13.7, df=4, p = 0.0002) . 
Regarding the pyoverdine production per cell per unit of time (Fig 3.20), in the 
absence of exogenous pyoverdine supplementation, no differences in the dynamics were 
detected in ΔfpvA or MPAO1 independently of the genetic construction added in the Tn7 
location. Nevertheless, the overexpression of the FpvB receptor reduced the amount of 
pyoverdine required to reach the maximum growth rate, both in ΔfpvA (t=30.68, df=4, p 
< 0.0001) and MPAO1 (t=6.6, df=4, p = 0.0027) (Fig 3.21, note the difference in scale). 
As seen in Fig 3.20, when exogenous pyoverdine was added, no difference in the 
pyoverdine requirements were detected, as no pyoverdine was required to reach the 
maximum growth rate. Regarding the production dynamics, in the absence of the receptor 
ΔfpvA the strains presented an initial steady state of production, up to 10 hours, when an 
increase in production was detected up to late stationary phase. When FpvB was over 
expressed, the dynamics became more similar to those of MPAO1, in which no 
pyoverdine is produced, up to a point in mid exponential phase, when de novo synthesis 
of pyoverdine began up until late stationary phase (Fig 3.20).  
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Figures 3.17, 3.18 and 3.9: Analysis of the influence of FpvB overexpression on 
bacterial growth in iron limited CAA with and without pyoverdine 
supplementation: Bacteria were transferred to fresh CAA from mid-exponential phase in LB 
and grown at 37°C and 500 rpm for 20 hours. OD600 was measured every 30 minutes. OD and 
growth rate curves were respectively fitted and generated using Fitderiv. Error bars represent 
standard error of the mean from three biological replicates.      
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Figures 3.20 and 3.21: Analysis of the influence of FpvB overexpression on 
pyoverdine production in iron limited CAA with and without pyoverdine 
supplementation: Bacteria were transferred to fresh CAA from mid-exponential phase in LB 
and grown at 37°C and 500 rpm for 20 hours. OD600 and fluorescence were measured every 30 
minutes to obtain pyoverdine production per cell per time point. Pyoverdine production per cell 
up to maximum growth rate was obtained calculating the area under the curve (AUC) up to that 
time point. Error bars represent standard error of the mean from three biological replicates 
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3.3.2.2- Consequences of the alteration of the expression of the secondary 
pyoverdine receptor (FpvB) in the presence of gentamicin 
Following the same procedure, the influence on growth and pyoverdine production 
kinetics of the overexpression of FpvB in the presence of gentamicin (20 µg/mL) was 
studied in the same conditions and with the same strains. This test aims to elucidate 
whether expressing additional amounts of FpvB could be beneficial for ΔfpvA or MPAO1. 
Both in the presence and absence of exogenous pyoverdine, bacterial growth was 
similar to that in the absence of gentamicin for ΔfpvA (Fig 3.17), in which the 
overexpression of FpvB yielded a distinguishable advantage in growth (Fig. 3.22), with 
maximum growth rates clearly higher and reached earlier in time when compared to the 
parental strain carrying only gentamicin resistance (Fig. 3.23). As such, significant 
differences were found between the strain overexpressing FpvB and that carrying only 
gentamicin resistance in the absence (t=4.282, df=4, p = 0.0128) or presence (t=6.609, 
df=4, p = 0.0027) of exogenous pyoverdine (Fig. 3.24). 
As seen in Fig. 3.22, for MPAO1, in the absence of exogenous pyoverdine, 
overexpression of FpvB resulted in a decreased growth capacity. Statistical analysis 
(t=4.472, df=4, p = 0.011)) returned significant differences in maximum growth rate 
between MPAO1 strain carrying an extra copy of fpvB and the strain carrying only 
gentamicin resistance (Fig. 3.24). When the medium was supplemented with pyoverdine, 
MPAO1 overexpressing FpvB still presented a growth delay (Fig. 3.24). In this case, 
maximum growth rate did not correspond to the order of growth, given that the MPAO1 
strain overexpressing the secondary receptor had a higher maximum growth rate. Indeed, 
significant differences were detected between the extra fpvB carrier and the MPAO1 
strain carrying only the gentamicin resistance (t=3.826, df=4, p = 0.0187) in favour of the 
former. 
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Regarding the dynamics of pyoverdine production per cell per unit of time (Fig 
3.25), in the absence of exogenous pyoverdine supplementation, no differences were 
observed in the ΔfpvA strains until late exponential phase, when dynamics started to 
diverge. Once exogenous pyoverdine is added, the ΔfpvA strains maintained a similar 
dynamic to that in the absence of gentamicin, although with slightly lower values of 
pyoverdine production overall. The analysis of the pyoverdine requirements to reach the 
maximum growth rate revealed that, either when supplemented with pyoverdine (t=8.917, 
df=4, p = 0.0009) or in its absence (t=33.35, df=4, p = 0.0001), carrying an extra copy of 
FpvB resulted in significantly lower pyoverdine production required to reach the 
maximum growth rates (Fig. 3.26).  
As seen in Fig 3.25, for MPAO1 strains in the absence of pyoverdine 
supplementation, two similar dynamics were detected, although at different times as the 
MPAO1 strain carrying an extra fpvB copy had a later pyoverdine production. Indeed, 
this strain required a significantly higher production of pyoverdine in order to reach its 
maximum growth rate (t=5.789, df=4, p = 0.0044) (Fig. 3.26). When pyoverdine was 
added, the MPAO1 strains decreased their capacity to grow out of the supplemented 
pyoverdine (shallower valleys when reaching mid-exponential phase) (Fig 3.25). The 
exogenous pyoverdine allowed the MPAO1 strains to reach their maximum growth rate 
with a negligible pyoverdine de novo synthesis. 
These results highlight the relevance of the balance of receptors, and that the 
interplay between the expression of receptors can be used to alter growth dynamics. 
Particularly, it was possible to drive FpvB compensation further in an ΔfpvA strain, 
leading to a fitter strain with better growth capacities and reduced pyoverdine production 
when compared to a normal ΔfpvA. On the contrary, overexpression of FpvB in an 
MPAO1 strain resulted in detrimental effects 
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Figures 3.22, 3.23 and 3.24: Analysis of the influence of FpvB overexpression on 
bacterial growth in iron limited CAA with and without pyoverdine supplementation 
in the presence of 20 µg/mL of gentamicin: Bacteria were transferred to fresh CAA from 
mid-exponential phase in LB and grown at 37°C and 500 rpm for 20 hours. OD600 was measured 
every 30 minutes. OD600 and growth rate curves were respectively fitted and generated using 
Fitderiv. Error bars represent standard error of the mean from three biological replicates. 
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Figures 3.25 and 3.26: Analysis of the influence of FpvB overexpression on 
pyoverdine production in iron limited CAA without pyoverdine supplementation in 
the presence of 20 µg/mL of gentamicin: Bacteria were transferred to fresh CAA from mid-
exponential phase in LB and grown at 37°C and 500 rpm for 20 hours. OD600 and fluorescence 
were measured every 30 minutes to obtain pyoverdine production per cell per time point. 
Pyoverdine production per cell up to the maximum growth rate was obtained calculating the area 
under the curve (AUC) up to that time point. Error bars represent standard error of the mean from 
three biological replicates. 
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Chapter IIIb: Characterization of costs 
and benefits of pyoverdine synthesis in 
monocultures. Role of receptors. 
Discussion. 
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3.4- Initial characterization of the strains in CAA: growth, growth rates and 
pyoverdine production 
It is widely accepted that the synthesis of pyoverdine is coupled to the reception of 
ferri-pyoverdine through the FpvA receptor, which in turn, releases the PvdS and FpvI 
sigma factors, respectively increasing the synthesis of pyoverdine and FpvA (58). As 
stated in the introduction, the secondary receptor FpvB, which shares a 54% amino acid 
sequence similarity with FpvA (94) has been largely ignored (the term FpvB only returned 
7 hits in Pubmed at the time of writing), leading to a complete lack of information 
regarding regulation, structure and/or function of this protein. Given that receptors are the 
carriers of benefits in the pyoverdine uptake, it is expected that they would participate in 
the evolutionary dynamics of pyoverdine producers in CF patients. 
In 2015, Andersen(64) described how these aforementioned social interactions 
shaped the evolution of the P. aeruginosa pyoverdine system in two collections of isolates 
from CF patients in which pyoverdine was or not detected in the sputum: in samples 
obtained from early stages of the infection, when pyoverdine was present, the synthesis 
of the FpvA receptor was maintained but, if pyoverdine was absent, then mutations in the 
receptor arose and blocked the ability to uptake pyoverdine (64). Unsurprisingly, the ratio 
between the observed mutations and the expected mutations assuming a random 
distribution was significantly higher only for the pvdS and fpvA genes (64). Following the 
inactivation of the pyoverdine system, iron acquisition is generally privatized through a 
switch to an iron-heme uptake system, which is upregulated through mutations in its 
regulator (65). In addition, the inactivation of the fpvB gene in the form of partial or larger 
deletions including fpvB and adjacent genes has been detected in clinical isolates in 
Belgium (95). 
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The initial results (Fig. 3.1) indicate that in the absence of exogenous pyoverdine, 
where costs and benefits shape the outcome, growth in iron limited CAA was extremely 
poor for ΔpvdA compared to producer strains, as expected based on previous works (137). 
Surprisingly, the opposite effects are observed when analysing ΔfpvA and ΔfpvB, having 
the former a delayed growth (as described by (94)) while the latter presented a very 
similar growth to that of the wildtype MPAO1. 
 Traditionally, the determination of the pyoverdine production per cell per time unit 
has been used to account for the total production of pyoverdine (137). Here, the amount 
of pyoverdine required to reach the maximum growth rate was also calculated, which 
indeed leads to a different perspective on the results obtained in this work, giving the 
relative investment required by each of the strains in order to obtain optimal growth. 
Based on pyoverdine production per cell over time (Fig. 3.4), one could argue that ΔfpvA 
does not produce enough pyoverdine, hence the delayed growth. Nevertheless, when 
analyzing the amount of pyoverdine required to reach the maximum growth rate (Fig 3.5), 
ΔfpvA produced the largest amount. Therefore, my data seems to indicate that the existing 
compensation with the secondary receptor when lacking the primary is not enough to 
sustain the growth rate, given that the highest pyoverdine production does not translate 
into the best growth, forcing the cells to accumulate even more pyoverdine. 
Little is known either about the dynamics of pyoverdine production for the mutants 
ΔfpvA and ΔfpvB. For ΔfpvA and despite all the studies carried out to understand its 
regulation and function (84,85,138), only two clear references about pyoverdine 
production by ΔfpvA  were found. First, “fpvA mutant produced lower amounts of 
pyoverdine than wildtype (Table 2), as has been observed by others (K.  Poole, personal 
communication)” (139) and second: Fig. 5-A in (80), depicting a decreased total 
production compared to the MPAO1, which nonetheless is in accordance with my results, 
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when considering pyoverdine production per cell and time  (Fig. 3.4). To my knowledge 
there is no information available for ΔfpvB. 
The supplementation with exogenous pyoverdine provides information about the 
ability of the receptors to uptake the siderophore, given that the cost of synthesis is 
alleviated, and therefore only the benefits obtained through pyoverdine reception shape 
the outcome. This is reflected by the fact that the strains reached the maximum growth 
rate before the pyoverdine production could be detected (Fig. 3.4). Nevertheless, ΔfpvA 
still presented a delayed growth (Fig. 3.1) and a  lower maximum growth rate (Fig. 3.2), 
again suggesting the ineffective compensation of the mutation in the primary receptor 
with the secondary, which fails to sustain full growth capacities in the range of time when 
there is no de novo pyoverdine synthesis (required to reach the maximum growth rate). 
Although indirectly, this idea is reinforced by the fact that the ΔfpvA strain presents 
pyoverdine uptake rates almost seven times lower than a wildtype strain and pyoverdine 
synthesis rates five times lower than the wildtype strain (96). 
Another possible explanation for the ΔfpvA results relates to the presence of 
pyocins, Pseudomonas bacteriocins that kill non-immune P. aeruginosa strains. The 
wildtype MPAO1 has three loci encoding soluble pyocins (S2, S4 and S5) and its 
immunity proteins (140). Several of these pyocins use pyoverdine (S2, S3 and S4) and 
pyochelin receptors (S5) to gain access to the cell (140–142). The results using 
transcriptional fusions suggest that the loss of the primary receptor leads to an increased 
expression of FpvB, which could act as a gate for self-produced or exogenous pyocins 
altering the balance between the pyocins and the immunity proteins. Indeed, R type 
pyocins (which enter the cell through lipopolysaccharides or lipooligosaccharides) have 
been found crucial for strain dominance in biofilms (57,143). In line with this idea, 
Dingemans (95) suggested the same reason for the selection of ΔfpvB clones in Belgian 
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reference centers (95). On the other hand, Ghoul (144), argued that bacterial dominance 
cannot be achieved through pyocin production in CF patients, but no studies allow a 
systematic investigation of this phenomenon correlating different stages of the disease, 
pyoverdine production and receptor expression. 
A recent study supported the idea of pyoverdine receptors as gates for different 
molecules, since it was described that a thiopeptide with antibiotic properties named 
thiostrepton was able to enter the cell using both FpvA and FpvB receptors, indicating 
that there might be molecules affecting growth able to use both receptors other than 
pyoverdine (145). 
In light of these results it is possible to answer the questions that originated these 
set of experiments. As demonstrated, losing FpvA (primary pyoverdine receptor) when 
the strain still produces pyoverdine results in detrimental growth, which will not be 
favored by evolution, and therefore it should not succeed in invading a wildtype 
population. The scenario generated when losing FpvB was neither detrimental nor 
beneficial, as the ΔfpvB strain did not improve MPAO1, therefore being unlikely to 
outperform a wildtype strain. Still an explanation is required for why ΔfpvB strains can 
emerge in CF patients (95) if, in theory, no advantage is obtained as a result of the 
mutation, except where big deletions are involved and fitness could be improved if these 
deletions cause a decrease in the costs of survival. 
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3.5- Effect of gentamicin supplementation on growth, growth rates and 
pyoverdine production 
Environmental stressors are key factors shaping bacterial evolution. Extrinsic 
changes that result from fluctuations in abiotic factors (natural or from human origin) are 
regarded as the most important ones, although they usually act in conjunction with biotic 
factors (competition, parasitism, etc.) (146). Among them, those affecting bacterial 
antibiotic resistance, such as iron concentration (147) or population structure and 
community interactions (148,149), are of clinical relevance because they can increase or 
diminish antibiotic effectivity.  Similarly, it is important to understand how the presence 
and management of antibiotics can drive the evolution of the community (e.g presence of 
dominant clones (150)), if evolutionary medicine wants to be considered as an alternative 
to traditional treatments.  
A previous work reports that in the case of P. aeruginosa, subinhibitory 
concentrations of gentamicin, in limited iron unstructured environments, can alter 
pyoverdine cooperative strategies, facilitating ΔpvdD (pyoverdine non-producer) 
dominance, an outcome reversed in the absence of antibiotic (136). This work is of pivotal 
importance, given that aminoglycosides (tobramycin, gentamicin and amikacin) are one 
of the main treatments for CF patients with P. aeruginosa infections (151). Indeed, it 
acquires more relevance given the ability of P. aeruginosa to  generate multiple resistance 
mechanisms to most of the antibiotics, leading to an increased prevalence of multi and 
extensively drug resistant lineages (152,153). 
In this scenario, I investigated what would be the evolutionary outcome if MPAO1, 
ΔfpvA and ΔfpvB (all pyoverdine producers) were grown in iron limited CAA in the 
presence of gentamicin, while they carried the acc3 resistance gene.  
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The presence of gentamicin increased the synthesis of pyoverdine per cell in all the 
strains (Fig 3.12). The analysis revealed that again, the ΔfpvA mutant required of the 
highest amount of pyoverdine synthesis to reach its maximum growth rate (Fig 3.13). The 
ratio of pyoverdine investment to maximum growth rate between both conditions 
(absence and presence of gentamicin) was calculated (Fig 3.14), revealing that the 
investment in pyoverdine of the wild type MPAO1 in order to reach the maximum growth 
rate multiplied by 30 times in the presence of gentamicin, compared to approximately 2.5 
times in the other two strains. 
The first question arising in view of these data is why pyoverdine production is 
increased when gentamicin is present, even when the strain is resistant to it. It is important 
to note that susceptibility to a great number of antibiotics (including tobramycin) is not 
altered by deletions of either of the pyoverdine receptors, discarding them as the entry 
point for gentamicin (95). Nevertheless, the susceptibility tests leading to that conclusion 
were performed on LB plates, in which iron was not limiting, and this might affect the 
results. A promoterless mini-Tn5-luxCDABE P. aeruginosa PAO1 mutant library 
revealed an increased expression of genes related to pyoverdine synthesis, pyochelin and 
pyocins when exposed to subinhibitory concentrations of gentamicin and tobramycin 
(154,155). Although valuable, the information reported by these studies is not directly 
comparable to my observations, given that bacteria were grown on LB and analyzed in 
mid-exponential phase, limiting the information of iron regulated genes (e.g pvdS or 
fpvA). 
 Early studies described the uptake of gentamicin as a three-step kinetic process, 
which can be altered in E. coli by the concentration of NaCl of the medium, in such a way 
that low concentrations of NaCl can increase the accumulation of gentamicin in the cell 
(up to 50 times after 60 minutes for E. coli in nutrient broth supplemented with 20 µg/mL 
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of gentamicin) (156). In fact, aminoglycoside treatment and the corresponding protein 
mistranslation seem to be the cause of membrane damage in E. coli, leading to an 
increased penetration of the antibiotic (157,158). In the case of  P. aeruginosa, 
membranes can be permeated by the displacement of Mg2+ and Ca2+ cations by 
gentamicin, generating a series of transient pores, facilitating further gentamicin 
accumulation (159).  
 It is well established that aminoglycosides act by blocking protein translation. In 
the specific case of gentamicin, significant rates of mistranslation leading to misfolding 
are detected in the presence of the antibiotic (160), which has been linked to protein 
aggregation. Probably as a consequence of protein aggregation, the presence of 
gentamicin increases oxidative stress, which is a common mechanism triggered by several 
antibiotics (161). Interestingly, the increase in pyoverdine production without secretion 
(no distinction between secreted and accumulated pyoverdine was made in the 
experiments presented in this dissertation) has been linked to oxidative stress caused by 
exposure to UV light and antibiotics – including gentamicin – (162). Generation of 
reactive oxygen species (ROS) could potentially affect iron-sulfur clusters, releasing 
ferrous iron,  and generating  hydroxyl radicals (OH·)  through the Fenton reaction (162). 
Therefore, the accumulation of pyoverdine would reduce the impact from the Fenton 
reaction and decrease the detrimental impact of hydroxyl radicals, the most powerful of 
ROS, on proteins, lipids, DNA, and RNA (163).  
This correlates with the fact that clinical strains isolated from CF patients presented 
augmented relative pyoverdine production if they were also sensitive to gentamicin, while 
isolates resistant to the antibiotic presented reduced amounts of pyoverdine (164). The 
latter can be explained based on resistance mechanisms preventing gentamicin 
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accumulation within the cell through porin downregulation or efflux pumps upregulation 
among others (50).  
Fig. 3.9 shows that all strains were affected by the presence of gentamicin, which 
translated in longer lag phases and decreased maximum growth rates (Fig. 3.11) when 
compared to the condition where no gentamicin was present. Even in the presence of 
exogenous pyoverdine, a condition in which the costs of pyoverdine synthesis are 
alleviated, longer lag phases and decreased maximum growth rates were also detected, 
indicating a direct effect of gentamicin on the acquisition of benefits (Fig. 3.11). As 
shown, not all strains were equally affected, which implies that when gentamicin is 
present, having the complete genetic circuit (that is, both receptors) is severely 
detrimental for bacterial growth, even when the strains are resistant to the antibiotic.  In 
this scenario, the sudden differentiation between ΔfpvB and MPAO1 growth (Fig 3.9) is 
an interesting phenotype that will be explained in the next section. 
 
3.6- Pyoverdine primary (FpvA) and secondary (FpvB) receptors: expression 
dynamics. Exploitation as tools to alter growth and pyoverdine production 
dynamics 
 
 As discussed before, the FpvB receptor is less efficient than FpvA, possibly due to 
a lower pyoverdine uptake rate or to the action of pyocins produced by the bacteria that 
target the secondary receptor. In order to gain mechanistic insights into FpvB function, 
transcriptional fusions were generated for both receptors and inserted in each of the 
strains. As expected, both receptors were upregulated in CAA (94) and the switch in 
expression when one of them is missing was evident (Fig 3.15).  
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Although it FpvA has been widely described as the primary receptor of pyoverdine 
(probably because it is directly linked to pyoverdine production, also lying within the 
same gene cluster) (85,138,165), it does not mean that it is its main receptor. By 
standardizing the  ribosome binding sites of the transcriptional fusions with a bicistronic 
linker, it is possible to directly compare promoter activities, since translation rates are 
normalized (130). Assuming this and pulling both transcriptional signals together, my 
results indicate that in the absence of gentamicin, the transcriptional signal of FpvB is 
close to 64% of the combined transcriptional signal of both receptors in MPAO1. Once 
gentamicin is added, forcing a higher pyoverdine production, FpvA transcription signals 
became close to the 85% of the pooled transcriptional signal for both receptors (Fig 3.15).  
This behaviour can be linked to the fact that FpvB expression, although blocked by 
Fur in the presence of iron, is regulated by an unknown mechanism (94). Analysis of the 
regulatory network of 10 different sigma factors including RpoD, FecI, PvdS and FpvI 
did not solve this question, although the amount of sigma factors encoded by P. 
aeruginosa is thought to be 25, and it is therefore not possible to rule the participation of 
an additional factor out (89). As basal levels (undetectable in the plate reader) of 
pyoverdine are produced during the early stages of growth, some iron molecules are 
initially chelated. These ferripyoverdine molecules need to stochastically find a bacterium 
and bind a minority of FpvA (also expressed in basal levels at that stage) coexpressed 
with a majority of FpvB receptors on the membrane surface, which will trigger the 
synthesis of more pyoverdine and more FpvA through the release of PvdS and FpvI. 
Iterations of this process will cause a shift in the interaction between sigma factors and 
the RNA polymerase, as a higher proportion of PvdS and FpvI will bind the RNA 
polymerase, facilitating the transcription of FpvA and its dominance on the membrane. 
Indeed, PvdS is able to reach 62% of the RpoD levels, but due to its poor binding to the 
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RNA polymerase and a considerable a proportion of the regulator being bound to FpvR, 
only < 2.3% of the total RNA polymerase is complexed with PvdS (80). Therefore, a 
considerable amount of PvdS needs to be produced to minimally displace the equilibrium 
in order synthesize pyoverdine and FpvA receptors.  
Before and while this shift takes place, it is likely that cells use FpvB as their main 
pyoverdine receptor, which according to my results is not as efficient as FpvA, therefore 
delaying bacterial growth. The redundancy in receptors and transport systems is not rare 
in biological systems. An extreme case would be Saccharomyces cerevisiae presenting 
up to 17 glucose transporters with different affinity (Michaelis-Menten) constants (166). 
In P. aeruginosa, several transporters for malate, fumarate and succinate have been 
described, and the alteration of these transport systems yielded different results in 
competition studies depending on the concentration of the substrates (167). In addition, 
single point mutations in multiple FpvA regions and the deletion of the gene caused 
alterations in the transport efficiency and pyoverdine synthesis (168). Therefore, it would 
not be surprising if both pyoverdine receptors presented different kinetic properties. 
To test whether the switch in receptors takes place, the transcriptional fusions were 
inserted into the mutant in the synthesis of pyoverdine  ΔpvdA (Appendix, Fig.3) and the 
results indicate that in the absence of pyoverdine, when cultured in iron depleted 
environments, FpvB expression is dominant, probably as a strategy to to take advantage 
of other sources of pyoverdine that could be found (e.g. a cooperative strain), even when 
having a very limited growth probably sustained by the pyochelin system. 
Consequently, four different situations can take place based on pyoverdine 
supplementation. In the first scenario (CAA), MPAO1 and ΔfpvB behave in a similar 
manner, and an affordable production of pyoverdine is required to reach the best possible 
cost-benefit ratio, coincident with the maximum growth rate, despite the imbalance of 
81 
 
receptors in MPAO1. In the second scenario, where CAA is supplemented with 
pyoverdine, the growth profiles depend only on the ability of the strains to obtain the 
maximum possible benefit through the combination of receptors. When CAA is 
supplemented with gentamicin, due to increased pyoverdine production, MPAO1 
probably goes through a longer transition (hence the increased lag) from an inefficient 
uptake system (FpvB majority) to a competent one (FpvA dominance), prior to reaching 
the most efficient growth in terms of cost-benefit ratios, something that ΔfpvB does not 
need to do since all the pyoverdine is funneled through FpvA. Finally, CAA 
supplementation with pyoverdine and gentamicin yielded a final scenario where 
pyoverdine is not able to fully restore growth due to the effect of gentamicin. 
In addition, the delay in growth could be also linked to pyocins. As revealed by 
Figs. 3.15 and 3.16, in the presence of gentamicin the transcription signals in absolute 
values were higher for FpvB receptors in the MPAO1 than when gentamicin is absent, 
which could lead, as mentioned before, to an imbalance between the uptake of pyocins 
and the synthesis of immunity proteins resulting in a delay in growth until FpvA becomes 
dominant. Indeed, the sudden increase in receptor expression in MPAO1 caused by the 
presence of gentamicin could lead to a situation where an overcrowded membrane 
impedes respiration (particularly if the receptors expand inside the periplasm up to the 
inner membrane) causing a delay in growth (169,170).  
These results prompted the alteration of growth dynamics by varying the proportion 
of receptors in the cell in order to obtain a strain with improved capabilities, able to 
overtake a wildtype population.  To the best of my knowledge, this strategy has never 
been tested in the pyoverdine system. 
Given that in absolute terms ΔfpvA produced the lowest amount of pyoverdine, I 
used this strain for the overexpression of FpvB under the control of a strong constitutive 
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promoter named 14F, under the assumption that a higher amount of the FpvB receptor, 
could compensate the lack of FpvA. According to my results, both in the absence and 
presence of gentamicin, the overexpression of FpvB resulted in a clear growth advantage 
for ΔfpvA (Figs. 3.17 and 3.22). In addition, the amount of pyoverdine required to reach 
the maximum growth rate was reduced in both conditions (Figs. 3.21 and 3.26), with total 
amounts of pyoverdine production also reduced (Figs. 3.20 and 3.25). These results 
indicate that the compensation of receptors by overexpressing FpvB in ΔfpvA was 
successful, therefore producing a more efficient strain with a greater potential to 
outcompete a wildtype strain while producing minimal amounts of pyoverdine. 
The overexpression of the FpvB receptor in MPAO1 yielded some counterintuitive 
results. In the absence of gentamicin, the overexpression of FpvB did not result in 
detrimental effects either in the presence or absence of exogenous pyoverdine (Fig 3.17). 
Indeed, without pyoverdine supplementation, for the same production dynamics, less 
amount of pyoverdine is required to reach maximum growth rate (Fig 3.21). It is 
important to highlight, that the AUC values for these MPAO1 strains are 2-logs lower 
than for ΔfpvA strains and therefore, this result might not correspond to an actual 
biological effect, perhaps reflected in minimal changes in maximum growth rate. In fact, 
the values are so low that differences might be the result of the experimental error.  As 
mentioned before, in this condition in which not too much pyoverdine and FpvA are 
required, the expression of FpvB constitutes already 64% of the transcriptional signal and 
the overexpression of the secondary receptor might not cause any effect. 
On the other hand, as expected for the MPAO1 strains when there was no 
pyoverdine supplementation, the addition of gentamicin caused a detrimental effect once 
FpvB was overexpressed, while increasing the amount of pyoverdine required to reach 
the maximum growth rate and decreasing the maximum growth rate, probably due to the 
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imbalance of receptors and the difficulty to shift to a higher FpvA expression (Figs 3.22, 
3.24 and 3.26). Interestingly, when pyoverdine was added, the overexpression of FpvB 
still caused a greater delay, whereas the maximum growth rate increased (Figs 3.22 and 
3.24). 
These results highlight the potential of some strains to outcompete a wildtype strain 
under stress induced conditions, revealing the dynamics of receptor compensation and its 
impact on growth efficiency. The clear differences in growth and pyoverdine production 
strongly suggest a differential cost/benefit ratio and the time to reach that point (lag phase) 
that could serve as a mechanism to allow fitter strains to grow and exhaust the communal 
resources. 
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Chapter IVa: Competition studies. Results. 
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4-Competition studies 
Following the characterization of all the strains (monocultures) in iron limited 
CAA, with and without the exogenous supplementation of pyoverdine, the mutant strains 
were competed against MPAO1 in unstructured environments (batch liquid cultures), 
semi-structured environments (static biofilms) and structured environments (Galleria 
mellonella), given that it has been widely reported that structure influences the evolution 
of cooperative populations.  
4.1-Competition experiments with and without gentamicin supplementation 
in unstructured environments 
Gentamicin resistant GFP and RFP tagged strains were grown overnight in LB, and 
transferred to fresh LB. Once mid-exponential phase was reached, cells were washed in 
PBS, mixed in a 0.85:0.15 (MPAO1: mutant) initial proportion and transferred to iron 
limited CAA, with and without gentamicin supplementation. Samples were taken and 
analyzed in the flow cytometer to assess the evolution of the proportions of each of the 
strains over time. Initial (t = 0) and final (t = 48 h) proportions of each strain were 
compared, as well as specific time points between strains (t = 18 h) 
As shown in Fig. 4.1, the presence of gentamicin greatly affects the behavior of the 
strains, altering the outcome of the experiment. The ΔpvdA non-producer strain was used 
as a control since non-producer behavior in iron poor CAA with and without antibiotic 
stress has already been described (136,162). As expected, in the absence of gentamicin, 
a minimal reduction in the percentage of MPAO1 (from 85.1% ± 1.7% to 80.94% ± 3.42) 
was detected, leading to non-significant results when comparing initial and final 
timepoints (T = 1.087, df = 4, p = 0.338). 
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In the presence of gentamicin, however, the frequency of MPAO1 decreased after 
48 hours to the verge of extinction (from 86.35% ± 1.51% to 1.12% ± 0.21%), generating 
a significant difference in its abundance between the beginning and the end of the 
experiment (T = 55.7, df = 4, p < 0.001).  
When challenged against MPAO1 in the absence of gentamicin, the ΔfpvA producer 
strain reached almost extinction, from an initial proportion of 13.9% ± 1.46% to 0.67% ± 
0.08%. Gentamicin supplementation lead to different evolutionary dynamics, in which 
ΔfpvA initially increased its frequency to a 44.18% ± 6.39% after 18 hours, just to 
drastically drop down to 7.72% ± 0.76% in the following 6 hours (24 hours in the 
experiment) and continued declining until the end of the experiment (0.67% ± 0.08%). 
This behavior was mirrored by MPAO1 strain, whose proportion decayed from an initial 
86.5% ± 0.32% down to 55.81% ± 6.38% in the first 18 hours, just to recover to 92.27% 
± 0.76% in the following 6 hours (24 hours in the experiment). In the last day of the 
experiment, MPAO1 still increased its percentage within the population up to a final 
98.43% ± 0.69%. 
When comparing the initial and final percentages of each of the strains individually, 
the statistical analyses returned significant differences both in absence and presence of 
gentamicin (T = 9.4, df = 4, p = 0.007 and T = 15.87, df = 4, p < 0.0001). At 18 hours, 
the strains were compared to each other and the statistical analyses returned significant 
differences in the absence of gentamicin (T = 537.6, df = 4, p < 0.0001) whereas no 
significant differences were detected in the presence of gentamicin (T = 1.289, df = 4, p 
= 0.267). 
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Figure 4.1: Analysis of bacterial competition in iron limited CAA in the presence or 
absence of 20 µg/mL of gentamicin: Bacteria were transferred to fresh CAA from mid-
exponential phase in LB and grown at 37°C and 500 rpm for 48 hours, with sample collection at 
0, 18, 24 and 48 hours. Bacterial proportions were calculated based on at least 104 event counts 
in a flow cytometer. Error bars represent standard error of the mean from three biological 
replicates with alternate fluorescent tags (GFP and RFP). 
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Competitions between MPAO1 and ΔfpvB showed similar dynamics to those 
between MPAO1 and ΔpvdA in both conditions (presence/absence of gentamicin), despite 
the mutants being a producer and a non-producer respectively. The major difference was 
the ability of ΔfpvB to reach fixation levels within the first 24 hours (from 13.9% ± 1.83% 
to 97.9% ± 0.95%). No significant differences were found between the initial and final 
proportions of both strains in the absence of gentamicin (T = 0.003, df = 4, p = 0.99), 
whereas significant differences were detected in the presence of the antibiotic (T = 46.62, 
df = 4, p < 0.0001). 
Competitions between MPAO1 and ΔfpvA14FfpvB yielded similar dynamics to that 
between MPAO1 and ΔfpvA in both conditions (presence/absence of gentamicin). In the 
absence of gentamicin, the ΔfpvA14FfpvB strain reached almost extinction, from an initial 
proportion of 13.86% ± 1.41% to 0.65% ± 0.035%. Equally, in the presence of 
gentamicin, ΔfpvA14FfpvB initially increased to 62.5% ± 10.5% at 18 hours, to later drop 
down to 18.7% ± 4.86% after 6 hours (24 hours in the experiment), reaching almost 
extinction point at the end of the experiment (5.39% ± 4.85%). The MPAO1 strain 
percentage decayed from an initial 85.94% ± 1.25% down to 37.4% ± 10.58% in the first 
18 hours and recovered to 81.25% ± 4.89% in the following 6 hours (24 hours in the 
experiment). After the first 24 h, MPAO1 still increased its percentage within the 
population up to a final 94.6% ± 4.85%. In this case, when comparing the initial and final 
proportions of each of the strains individually, statistical analyses returned significant 
differences only in the absence of gentamicin but not in its presence (T = 9.33, df = 4, p 
= 0.007 and T = 1.719, df = 4, p = 0.16). At 18 hours, the strains were compared to each 
other and statistical analyses returned significant differences in the absence of gentamicin 
(T = 231.2, df = 4, p < 0.0001) whereas no significant differences were detected in the 
presence of the antibiotic (T = 1.68, df = 4, p = 0.167). 
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As additional information, mutants´ relative fitness for each time point (0,18,24 and 
48h) in the presence or absence of gentamicin have been included in Appendix Figure 
5. 
Finally, in order to ensure the reproducibility of the method, the competition 
between MPAO1 and ΔfpvA14FfpvB in the presence of gentamicin was repeated, and 
instead of using flow cytometry to calculate proportions, samples were plated on LB agar. 
This combination of strains and condition were selected due to the characteristic peak and 
sudden decrease in the proportions generated by ΔfpvA14FfpvB between 18 and 24 hours 
obtained when using the flow cytometer. As seen in Fig. 4.2, the same pattern is obtained, 
although the plating system presents larger errors when compared to flow cytometry, 
which is expected due to the inaccuracy of the method. A representative experiment in 
the flow cytometer can be seen in Appendix Figure 4. 
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Figure 4.2: Comparative results between FACS and plating: Bacteria were transferred 
to fresh CAA from mid-exponential phase in LB and grown at 37°C and 500 rpm for 24 hours, 
with sample collection at 0, 18 and 24 hours. Bacterial proportions were calculated either based 
on at least 104 event counts in a flow cytometer or after plating on LB plates following serial 
dilutions. Error bars represent standard error of the mean from three biological replicates with 
alternate fluorescent tags (GFP and RFP). 
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4.2-Competition experiments with and without gentamicin supplementation 
in semi-structured environments 
When competition experiments are performed using structured populations, results 
are different to those in unstructured populations, as in the latter, public goods diffuse 
freely and are equally accessible to every single member of the population (33,171). 
Again, gentamicin resistant GFP and RFP tagged strains were grown overnight in LB and 
transferred to fresh LB. Once mid-exponential phase was reached, cells were washed in 
PBS, mixed in a 0.85:0.15 (MPAO1:mutant) initial proportion and transferred to iron 
limited CAA, with and without gentamicin supplementation. Samples were then 
inoculated into a multichannel chamber (see Methods), grown for 48 hours and studied 
using a confocal microscope. These experiments were performed in order to obtain 
qualitative information on how structure could potentially alter the dynamics of the 
populations in the presence or absence of gentamicin. 
As a control, Fig. 4.3 shows representative images of the competition experiments 
between a GFP tagged MPAO1 and an RFP tagged ΔpvdA (non-pyoverdine producer). 
In the absence of gentamicin, after 48h, ΔpvdA did not dominate the population. Indeed, 
it seemed that non producer strains infiltrated in the center of MPAO1 micro-colonies. 
On the other hand, once gentamicin was added, ΔpvdA was able to outcompete MPAO1, 
whose growth can be barely detected, matching the results in unstructured populations.  
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Figure 4.3: Competition studies between MPAO1 and ΔpvdA: After 48 hours growing 
in iron limited CAA, cells were imaged using a Nikon A1M confocal microscope. MPAO1 was 
tagged using GFP and ΔpvdA using RFP. Each image is representative of a set of 10 randomly 
selected areas (selected using phase contrast to avoid bias) for each condition, taken for each 
biological replicate (2). Scale bars equal 20 µm.  
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The qualitative outcome of this experiment prompted us to test whether results 
would also replicate for ΔfpvA, ΔfpvB and ΔfpvA14FfpvB in the presence of gentamicin. 
In order to obtain quantitative data, green and red pixels were counted using the ImageJ 
plugin Color Pixel Counter. As seen on Fig. 4.4, ΔpvdA in the absence of gentamicin was 
unable to increase its frequency over 0.5. Once gentamicin was added, ΔpvdA and ΔfpvB 
red pixels reached frequencies over 0.9 whereas ΔfpvA and ΔfpvA14FfpvB remained 
below 0.5. 
As expected, significant differences were found between the frequency of red 
ΔpvdA pixels in the absence of gentamicin (used as a control) when compared to ΔpvdA, 
ΔfpvA, ΔfpvB and ΔfpvA14FfpvB red pixel frequencies generated in the presence of 
gentamicin (One-way ANOVA F = 68.18 p = 0.0002). Post-hoc Dunnett test revealed 
that those differences were significative for ΔpvdA, ΔfpvA14FfpvB and ΔfpvB (p=0.002, 
p=0.0268 and p=0.0002 respectively). The lack of significative differences for ΔfpvA 
might be attributable to a greater variability in the quantification. 
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Figure 4.4: Quantification of mutant frequency in semi-structured environments: 
Bars represent pixel frequency for red pixels (mutant strains). Each image is representative of a 
set of 10 randomly selected areas (selected using phase contrast to avoid bias) for each condition, 
taken for each biological replicate (2), from which standard error bars were generated. Scale bars 
equal 20 µm. 
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4.3-Competition experiments in structured populations: G. mellonella as 
animal model for P. aeruginosa infection 
In recent years G. mellonella has been used as a model for infection for several 
human pathogens, including P. aeruginosa (172). It has the advantage of reproducing 
more closely the spatial growth of P. aeruginosa during a real infectious process. Here, 
it was used to repeat the monocultures and some competition experiments between the 
different strains in the presence or absence of gentamicin. To do so I followed the standard 
protocol for infections in this model (173). Briefly, GFP and RFP tagged cells were grown 
overnight in LB at 37°C and then transferred to fresh LB. Once mid-exponential phase 
was reached, cells were washed, ODs normalized to 1 and then diluted so a 10 µl injection 
in G. mellonella would contain 102-103 bacteria. This guaranteed that founder members 
would be evenly distributed in the larvae and far enough from each other to prevent direct 
contact between colonies during the early stages of growth. Following this, a stock 
solution of gentamicin was diluted in saline solution (0.9% NaCl) to obtain a 20 µg/mL 
final concentration in the larvae after a 10 µL injection.  Larvae were incubated at 37°C 
and their survival was checked every hour for mono-infections. For competition 
experiments, cells were mixed in a 0.5:0.5 (MPAO1:mutant) proportion and the larvae 
were culled at 15 hours with the haemocoel being recovered, diluted and plated to 
calculate population percentages. 
Single strain infections were performed with MPAO1, ΔfpvA and ΔfpvB in order to 
understand the relevance of the presence of gentamicin in an animal host for each of the 
strains. Fig. 4.5 depicts the results of mono-infections as survival curves. Independently 
of the presence of gentamicin, the larvae died before 22 hours, except for the control 
group (no treatment at all) and the NaCl + gentamicin group. When comparing mono-
infections in the presence or absence of gentamicin, MPAO1 yielded significant 
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differences using long-rank test (Z = 2.19, p = 0.0283). On the other hand, ΔfpvA (Z = 
0.28, p = 0.78) and ΔfpvB (Z = 0.2, p = 0.84) curves did not yield significant differences. 
Given that it has been established that non-producers of pyoverdine cannot 
dominate the population when co-infecting G. mellonella or C. elegans (119,124), and 
that according to my results, ΔfpvA cannot overtake a MPAO1 population either, ΔfpvB 
was selected as the ideal candidate for competition experiments. 
As seen in Fig. 4.6, similar results were obtained independently of the gentamicin 
presence. The initial proportions of this experiment were 54.1% ± 3.8% : 45.9% ± 3.8% 
(MPAO1: ΔfpvB). After 15 hours ΔfpvB dominated the population:  23.6% ± 2.17% : 
76.4% ± 2.17% (MPAO1: ΔfpvB) in the absence of gentamicin and 20.3% ± 6% : 79.7% 
± 6% (MPAO1: ΔfpvB) with gentamicin supplementation. As expected, significant results 
were found between initial and final proportions for each of the strains: T = 6.86, df = 4, 
p = 0.0023 and T = 4.75, df = 4, p = 0.009 for the absence and presence of gentamicin 
supplementation respectively. Relative fitness for ΔfpvB between T0 and T15 was 
calculated for both conditions, yielding 3.37 ± 0.22 (SEM) and 5.88 ± 1.59 (SEM) in the 
absence or presence of gentamicin respectively. Statistical analyses revealed no 
significant difference in the relative fitness between conditions (T = 1.557, df = 4, p = 
0.1946). The relative fitness (v) of mutants was calculated as v = [t2(1−t1)]/[t1(1−t2)], 
where t1 is the initial proportion of mutants and t2 is their final proportion. The fitness 
value of v therefore signifies whether mutants increased in frequency (v > 1), decreased 
in frequency (v < 1) or remained at the same frequency (v = 1) over the competitive 
period. 
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Figure 4.5: Survival of G. mellonella during mono-infections: After initial infection, the 
survival of the larvae was monitored every hour. Those individuals not responding to physical 
pressure with plastic tips were considered dead, independently of the degree of melanisation. 
Lines represent the mean value of three biological replicates. Dotted lines represent confidence 
intervals (95%).          
     
 
 
 
 
 
98 
 
Figure 4.6: Initial and final proportions of MPAO1 vs ΔfpvB competition studies in 
G. mellonella: GFP and RFP tagged strains were serially diluted and plated on LB prior to 
injection in the larvae to account for the initial proportions. After 15 hours, larvae were placed in 
ice until they ceased moving. An incision was made to recover haemocoel, then serially diluted 
and plated on Pseudomonas Isolation Agar supplemented with 20 µg/mL of gentamicin. Colonies 
grew at 37°C for 18 hours and then kept at 4oC for three days to facilitate identification. Error bars 
represent standard error of the mean for 3 biological replicates with alternate fluorescent tags 
(GFP and RFP).           
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Chapter IVb: Competition studies. 
Discussion. 
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4.4-Competition studies 
 
Once demonstrated that the environmental conditions (e.g. presence of gentamicin) 
affect the strains in different ways when grown individually, I decided to proceed with 
competition studies. The rationale behind these experiments was to exploit the key 
differences in the growth of the different strains. For instance, mutants exhibit faster 
growth rates than the wildtype during balanced growth under certain conditions. In 
addition, the observed differences in the lag phases of the mutants and the wildtype strain 
in the presence of gentamicin are relevant for the kinetics of the competitions because it 
would be possible for those starting to grow earlier to dominate the population and 
exhaust the resources (despite having a lower growth rate in the exponential phase), thus 
preventing the growth of MPAO1. Moreover, conditions may change over time due to 
the interplay between the ecology and the evolution of the community. For example, as 
one of the populations thrives, the other may adjust its strategy to produce a different 
amount of the public good as reported previously for pyoverdine (124,137,174). I 
therefore hypothesised that growth properties in monocultures may not directly reflect 
the evolutionary outcome of a mixed culture, and I tested this hypothesis in competition 
experiments between each mutant and the wildtype MPAO1 in the presence or absence 
of gentamicin 
 In P. aeruginosa mainly two types of public goods have been widely considered 
for competition studies: QS induced molecules and siderophores (21,25,137,175). In 
general, cooperative strains have been competed against non-producer strains 
(21,33,137,176)or between producers with altered production (177) and to the best of my 
knowledge, no competition studies have been performed using the pyoverdine receptor 
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mutants ΔfpvA and ΔfpvB, hence their potential value as tools to alter population 
dynamics was unknown prior to this work. 
Four strains were initially competed against MPAO1: ΔfpvA, ΔfpvB, ΔpvdA and 
ΔfpvA14FfpvB. The initial proportions were selected based on the fact that lower initial 
frequencies facilitate cheater progression when competing against producer strains (63), 
although in the scenario described here the strains used are still producers to different 
extents. ΔpvdA was used as a control, and the results matched those already published for 
the same culture conditions, where addition of gentamicin facilitates non-producer 
dominance in 48 hours (136). However, the behaviour of ΔpvdA depends on the 
conditions as described in other works. For instance, apparently contradicting results were 
obtained when using succinate minimal medium without any iron chelator added, in 
which case the wildtype pyoverdine producer dominated the population in the presence 
of tobramycin (162). The discrepancies in the results can be explained by several reasons. 
Although the medium used in ((162)) has a low iron content (traces) similarly to CAA, it 
contains different carbon and nitrogen sources, which affect pyoverdine production (178). 
Also, growth in succinate minimal medium causes an increase in pH that can reach values 
near 8.5 at the end of the experiment (179). In addition, the lack of apotransferrin or other 
exogenous iron chelators in the medium described in (162) allows both strains to grow 
using the metabolically cheaper pyochelin system (178,180,181). As mentioned, it was 
not possible to find similar studies for the rest of the strains. Nevertheless, it is worth 
mentioning that in the bibliography, the role of a cheater (even between cooperators) has 
been assigned to any strain producing less of a public good and obtaining a lower benefit 
in the absence of a superior cooperator, which is a definition that might not fit some of 
the cases described in this report (177).  
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As seen in Fig 4.1 the progression of the ΔfpvA strain over the first 18 hours was 
suddenly stopped after 24 hours. Although this can be initially linked to the action of 
ΔfpvA facilitating the conditions for MPAO1 growth after a certain period of time 
(pyoverdine production and gentamicin inactivation through the acc3 resistance gene), a 
similar trend should have been observed in the competition between MPAO1 and ΔfpvB. 
Instead, in this second case the population of MPAO1 went almost extinct. These 
differences can be explained by the limited capability of FpvB to support growth 
compared to FpvA. A ΔfpvA mutant compensates for the lack of primary receptor by 
overexpressing the secondary receptor which is less efficient for pyoverdine uptake either 
because of its lower transport activity or because it is the target of toxins specific for the 
receptor. In any case, when MPAO1 starts growing at the expense of FpvA it has an 
advantage despite the longer lag phase. A similar dynamic can be detected, even more 
accentuated, in the competition between MPAO1 and ΔfpvA14FfpvB when after 18 hours 
the ΔfpvA mutant strain carrying an extra fpvB copy dominates the population, just to 
decrease to the initial frequency in the population in the followin six hours. Indeed, this 
result indicates that through the manipulation of receptors and improved benefit 
attainment it is possible to obtain strains with the ability to dominate a population – 
although in this case is temporarily – by altering growth dynamics. 
As described in the introduction, several mechanisms have been proposed through 
which cooperative individuals can control the spread of non-cooperative members in 
natural environments, such as reduced production of public goods, timing, policing, etc 
(20). In nature, bacteria usually grow attached to surfaces forming biofilms, in which the 
microorganisms are embedded in a polymeric matrix composed, among others, of 
exopolysaccharides, DNA and proteins. This matrix reduces the diffusivity of public 
goods, preventing its spread and concentrating them around cooperative lineages that 
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grow in a clonal manner. Therefore, the physical structure of a population can be a key 
factor preserving cooperation (33,123,171).   
The results of competition experiments in homogenous environments (liquid 
cultures) prompted us to continue studying the behaviour in structured environments, 
given that iron is essential for biofilm formation, and the lack of pyoverdine can greatly 
affect the 3D structure of the biofilm (99,182). Therefore, static biofilms were grown to 
obtain qualitative information. Growth of biofilms on plastic/glass surfaces while 
submerged in the corresponding media has been widely used to assess the ability of P. 
aeruginosa to form biofilms (183,184). Similar to the previous experiments in liquid 
media, competition studies between MPAO1 and the mutant ΔpvdA (the non-producer 
strain used as a control) in structured environments have been reported in previous works 
and showing the inability of the mutant to dominate the population in in vivo experiments 
(119,124).   
Fig. 4.3 shows that after 48 hours of incubation in the absence of gentamicin a 
minority of ΔpvdA cells are found and they are mostly surrounded by MPAO1. This 
phenomenon is not the result of the formation of mixed colonies due to the initial location 
of the cell-types in the colony, but to the active movement of non-producer strains into 
cooperative microcolonies, which has already been described within the same time frame 
(185). This probably chemotactically induced movement could be the strategy that non-
producer strains follow to increase their benefits in response to the limited availability of 
pyoverdine that is confined within the microcolony and only exchanged through direct 
contacts between members (186). This is particularly relevant because both my and Penn 
(185) experimental systems allow the bacteria to freely move and colonize other 
microcolonies while pyoverdine can still diffuse between microcolonies. Usually, the lack 
of potential to overtake a wildtype population in structured environments has been 
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attributed to the reduced diffusivity of pyoverdine (119,171,173), but given that non-
producers are able to reach the core regions of productive microcolonies, it would be 
expected that they would outcompete a wildtype cooperative strain, at least locally 
(micro-colony level). After nine days, the proportion of non-producers does not exceed 
that of producers, even when pyoverdine is continuously being washed forcing 
cooperative individuals to endlessly produce pyoverdine (185).  A potential explanation 
for this could be that within microcolonies, the pyoverdine is confined and directly 
exchanged between cells. As such, a gradient of pyoverdine is generated: the 
concentration is higher in the centre because cells on the edge of the colony have less 
neighbours to import from, and thus have lower siderophore levels, contributing with less 
pyoverdine to their direct neighbours (186). The presence of non-cooperative members 
in the centre of the microcolony could invert that gradient, explaining why the proportion 
of cheaters in microcolonies initially increases just to suddenly decrease over time until 
the last stages of a nine day experiment, when the proportions balance (185). Indeed, in 
later stages of the experiment, cheats begin to grow and accumulate outside 
microcolonies, reinforcing the idea that gradients might have been inverted (185). 
Moreover, even if pyoverdine was accumulated in the medium, a gradient is generated 
between the outside and the inside, again favouring cooperative cells in the outer region 
of the microcolony (185). The addition of gentamicin led to similar results to those 
obtained in batch cultures, where ΔpvdA became the dominant strain. This is expected as 
there is no associated pyoverdine cost or extra cost induced by the presence of the 
antibiotic. 
As seen on Fig. 4.4, the ΔfpvA strain was unable to overtake MPAO1 in the 
presence of gentamicin, and the presence of mutants within wildtype micro-colonies was 
also detected. This behaviour has not been described for this type of mutant and requires 
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further research, but a potential explanation would be that the ΔfpvA mutants could 
initially migrate to alleviate the costs of producing pyoverdine just to have their growth 
arrested by pyocins or other toxins. On the other hand, competition with ΔfpvB in the 
presence of gentamicin yielded results similar to those observed in unstructured 
conditions, in which the mutant presents a large growth advantage, probably consuming 
all the available resources before MPAO1 can reach its full growth potential. These 
results highlight ΔfpvB as the most suitable candidate for overtaking MPAO1 populations 
when gentamicin in present.  The novelty of these results relies in the fact that the ΔfpvA 
and ΔfpvB, mutants do not require the presence of a wildtype to be able to grow in 
structured environments (they are still pyoverdine producers), therefore having the 
potential to outcompete MPAO1 by having different cost/benefit ratios due to altered 
genetic circuits affecting the expression of pvd genes. 
The results obtained in artificial systems including structured environments are 
informative but might not be representative of in vivo scenarios in which interactions 
between the pathogen and the host (e.g immune system) are present. This limits the 
applicability of the findings described in previous sections and the reason for conducting 
in vivo experiments using an animal model to test a more representative condition of what 
would happen during an infection. 
 The animal models for P. aeruginosa infection studies included among others: 
mouse, rats, guineapigs, cats and monkeys (187). G. mellonella is a suitable model for 
infection given its advantages: easy to obtain, no feeding required, no ethical constrains, 
the possibility to study the activity of antimicrobials and a remarkably similar innate 
immune response to that of vertebrates (188). In addition, it has been demonstrated that 
P. aeruginosa´s virulence in G. mellonella correlates with that in mice (189). 
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From Fig. 4.5, it can be inferred that antibiotic administration only caused a 
significant difference in killing for MPAO1. These results need to be put into a biological 
context, and from that perspective, differences were minimal and might as well be 
irrelevant for competition studies. Two possible explanations emerge based on the 
relevant factors resulting from the previous in vitro studies. The first explanation may lie 
in the pharmacokinetics of gentamicin. Generally speaking, in CF patients a single daily 
gentamicin dose is administered in what is known as a “once-daily aminoglycoside” 
(ODA) (190). In an attempt to replicate that, and to minimize physical damage to the 
larvae, a single dose of gentamicin was injected after infection. Although information 
about the pharmacokinetics of aminoglycosides in G. mellonella is limited, in humans it 
is well accepted that its half-life falls between 2-3 hours (191). Interestingly, the half-life 
of the aminoglycoside amikacin in G. mellonella seems to be similar to that in humans 
(192). Therefore, the levels of gentamicin could have been greatly reduced by the time 
the bacterial cells start to grow therefore mitigating any potential differences in the killing 
time when comparing the infection dynamics in the presence and absence of the 
antibiotic. Moreover, besides the fact that the location of the injection of gentamicin is 
different from the location of the point of infection, G. mellonella possess an open 
circulatory system, which lacks many of the systems that pressurize a closed one (193). 
As such, the distribution of gentamicin might not be as homogeneous as in the in vitro 
models reported here. In addition, bacteria are expected to grow mostly forming biofilms, 
which has a severe impact on antibiotic effectivity due to the reduced penetration in 
microcolonies (194).  
A second explanation is linked to the presence of iron during infection. Little 
information is available regarding the iron content in G. mellonella, but the presence of 
transferrin has been described as part of the upregulated proteins during infection (195). 
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Iron availability might be greater than that of the in vitro models, reducing the need for 
pyoverdine production, thus alleviating the metabolic costs and not causing any 
differences in the killing when gentamicin is present. In fact, although the dissociation 
constant of the human apotransferrin with iron is known (196), no formal studies have 
been performed with G. mellonella.  
Interestingly, pyoverdine non-producers are still able to grow on their own and kill 
G. mellonella, with minimal differences in the killing (two hours) (124), revealing that 
iron could be accessible through pyochelin or other sources. This means that although 
pyoverdine helps to grow faster, it is not an essential iron acquisition system and has low 
relevance in the death of the larvae, which is probably caused by other unknown virulence 
factors. This theory is supported by a previous meta-analysis indicating that the lack of 
pyoverdine modestly reduced virulence in vivo in different models, particularly in 
invertebrates (66). Therefore, negligible differences in killing are expected when 
comparing our producer strains as it is the case, given that all produce and use pyoverdine 
(Fig. 4.5). 
The fact that in this scenario pyoverdine is not relevant for the killing dynamics 
does not mean that competition-cooperation dynamics are not taking place in the larvae, 
given that it still provides the producer strain with a certain fitness advantage (124), and 
optimized strains should obtain a greater benefit. As mentioned above, ΔfpvB had been 
the only strain able to consistently dominate the population in in vitro conditions and was 
used for competition experiments against the wild type in G. mellonella.  As shown in 
Fig. 4.6, the ΔfpvB strain was able to dominate the population after 15 hours. Previous 
results using canonical cheaters in G. mellonella and C. elegans indicated that invasion 
was not possible (119,124). Contrary to the expectation, this happened both in the 
presence or the absence of gentamicin, apparently contradicting my previous in vitro 
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results. Even though G. mellonella lacks an adaptive immune response present, it 
possesses a vertebrate-like innate immune system that could potentially generate the same 
stress situation as the one induced in-vitro by gentamicin (172,197,198). This will obscure 
the initial effect of the antibiotic but at the same time, maintain a certain degree of stress 
conditions that facilitate ΔfpvB dominance.  
Therefore, although the effect of gentamicin might not be present due to its 
pharmacokinetic properties, the experimental results suggest that G. mellonella can at 
least partly replicate the stress conditions that impact competition dynamics depending 
on the pyoverdine system even though these dynamics are not relevant for the survival of 
the larvae in the experimental conditions.  
Further research is required to analyse the relevance of initial densities and 
proportions, which can influence the outcome of the competitions. The role of these 
variables in the dynamics of competing populations are well known in a producer vs non 
producer interaction (62,63). However, in the case studied here it is not possible to 
describe who acts as a cheater in a producer vs producer competition, particularly if the 
strains are distributed in patches with limited pyoverdine diffusion (177). Equally, further 
work is required to understand whether it is possible to invade an already established 
population, since canonical cheats are unable to do it at later growth stages, when 
pyoverdine costs have been distributed among all the cooperative cells (137). Initial 
frequency values were selected based on the negative frequency dependence from the 
canonical cheaters. Although cheater progression is favoured by low initial frequencies, 
they must have the ability to succeed also when their frequency is higher if they are to be 
used as Trojan horses (121). ΔfpvB, contrary to canonical cheaters, is able to progress 
even at higher frequencies. My results indicate that the ΔfpvB strain is able to progress at 
high starting frequencies, which shows the great potential of this strain to be fixed in a 
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population of wildtype bacteria. Although virulence was not studied during competition, 
the use of ΔfpvB as an improved an efficient strain could perhaps show slight signs of 
virulence reduction resembling the presence of cheaters (118,124).  
Another advantage of using optimized producers is that as pyoverdine becomes 
more available, cheaters are expected to emerge, but in this case carrying the phenotype 
of the improved cooperator (e.g antibiotic susceptibility). These new emerged cheaters 
should decrease the virulence of the population and impose another burden to the original 
wildtype strain. 
Variables like density, frequency and duration of the experiments are fundamental 
for the success of invasive strategies and need to be properly understood if these strategies 
are to be used instead of (or combined with) traditional antimicrobial therapies. 
 
 
 
 
 
 
 
 
 
 
 
110 
 
Chapter V: Concluding remarks and future 
work. 
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The aim of this thesis has been to obtain a P. aeruginosa strain able to successfully 
overtake a wildtype population in structured environments. Previous approaches have 
focused on saving the cost of producing pyoverdine but in this case, I decided to focus on 
altering the benefits, under the premise that fitter strains would be able to succeed given 
that receptors are the actual carriers of the benefit (iron in this case). Contrary to previous 
studies, the novelty of this strategy comes given by the fact that mutants for pyoverdine 
receptors are still able to produce pyoverdine, allowing them to grow in the absence of a 
wildtype strain, resulting in no limitations imposed by structure. 
I performed competition experiments in three different environments: unstructured, 
semi-structured and in vivo (G. mellonella). The main reason for selecting these 
conditions was that most of the previous work describe unstructured environments 
although structure is a key element facilitating cooperative strategies. The results obtained 
highlight a complex scenario and, in particular, more information would be required about 
the dynamics of bacterial growth in an animal host for its use as an alternative treatment 
within the premises of evolutionary medicine.  
 Previously published results vary depending on the animal model considered. In 
this sense, it is important to decipher the relevance of the public good under study in the 
host chosen. As demonstrated in this dissertation, the lack of virulence variability does 
not imply that social dynamics are absent. As such, public goods with negligible impact 
on virulence can still be used as gates for Trojan horses.  In addition, there are a number 
of limitations in previous studies: many of them use strains labelled as PAO1, but after 
circulation in multiple labs for decades, the genotypes are likely altered. Equally, the 
defective strains used in several publications were generated by random mutagenesis 
using exposure to UV light, assuming that no mutagenesis happened in other loci. Off-
target effects could be avoided by producing clean directed deletions, and where possible, 
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in the same genes, given that is not the same to mutate a pyoverdine synthesis gene than 
pvdS, a key regulatory element affecting multiple traits. 
The characterisation of monocultures indicates that only under stress-induced 
situations (presence of gentamicin), the pyoverdine system can be used as a gateway to 
alter the dynamics of the population. This happens by the differential investments in 
pyoverdine generated by the presence of the antibiotic, which is higher in the wildtype 
strain compared to the mutants in the receptor proteins. The competition experiments 
revealed that the lack of FpvB was fundamental for the success in the three environments 
when gentamicin was present, given that all ferripyoverdine enters the cell through the 
primary receptor, which is arguably more efficient and linked to pyoverdine production.   
Based on the data collected with synthetically improved transcriptional fusions, a 
probable switch between secondary receptor and primary receptor takes place in the 
wildtype strain, likely affecting the time required to reach an optimal cost/benefits ratio. 
An in-depth analysis of the mechanisms of this switch requires further research in terms 
of transcriptional regulation and translation. Indeed, further research on thee FpvB 
receptor is required, given that nothing relevant has been added to the literature since its 
discovery. Some of the results indicate that FpvB could act as a gate for toxins, altering 
the results of the competition studies, potentially being part of the growth limiting factors 
for primary receptor mutants. These results also demonstrate that it is possible to 
manipulate the cost/benefit ratio by altering the expression of secondary receptors in a 
primary receptor mutant strain, which translates in a better growth and a lower pyoverdine 
production in the presence of an environmental stressor. This poses an initial advantage 
in competition studies compared to its parental strain. 
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Unlike previous studies, I have demonstrated that these dynamics take place even 
when the strains are resistant to gentamicin and not only when sublethal doses of the 
antibiotic are used on sensitive strains. This paves the way for novel antimicrobial 
therapies, in which antibiotics and optimized strains with reduced virulence and/or 
specific antimicrobial sensitivity are combined. Further research will be required to 
understand whether this is a common effect of all antibiotics, or it is only limited to 
gentamicin and aminoglycosides, as well as the mechanisms leading to it. It will be 
important to determine the relevance of the type of resistance mechanism, since this could 
affect the outcome. 
This work demonstrates that the role of receptors pyoverdine is of key relevance 
for growth dynamics. It demonstrates for the first time that pyoverdine receptors can be 
used as tools to optimize bacterial growth even in animal models in which the public good 
is not essential for invasion. Additional research is required to understand if this 
conclusion can be generalised to other public goods or other pathogens. These could 
include other iron uptake systems or diffusible public goods, like QS molecules, perhaps 
by overexpressing the regulatory/sensory proteins binding the signalling molecules, 
allowing to trigger an earlier quorum response. 
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Appendix Figure 1: pBG25-GFP/RPF-control14F and pBG25-GFP/RFP-14FfpvB, 
carrying Tn7 deliverable constructs for bacterial competition. 
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Appendix Figure 2: flow cytometry fluorescence controls: tagged MPAO1 bacteria 
were grown overnight in LB and transferred to fresh LB the following day. Once mid-
exponential phase was reached, samples were collected, washed and diluted in PBS. First 
row, SSC-A vs FSC-A scatter plots: 1- GFP+ population. 2- RFP+ population. 3- GFP+ and 
RFP+ populations overlaid. Second row, Ex:488 nm Em:530/30 nm histogram plots: 1- 
GFP+ population. 2- RFP+ population. 3- GFP+ and RFP+ populations overlaid. Third row, 
Ex:561 nm Em:620/15 nm histogram plots: 1- GFP+ population. 2- RFP+ population.  3- 
GFP+ and RFP+ populations overlaid. 
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Appendix Figure 3: Pyoverdine receptor activity in ΔpvdA in the presence of 20 
µg/mL of gentamicin: fpvA promoter (red) and fpvB promoter (blue) activity. Bacteria were 
transferred to fresh CAA and supplemented with 20 µg/mL of gentamicin from mid-exponential 
phase in LB and grown at 37°C and 500 rpm for 48 hours. OD600 and fluorescence were measured 
every 30 minutes to obtain mCherry production per cell per time point. 
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Appendix Figure 4: Representative MPAO1::Tn7:acc3:RFP:14F (RFP+/GFP- Q3) 
vs ΔfpvA::Tn7:acc3:GFP:14F (GFP+/RFP- Q1) competition experiment 
supplemented with gentamicin. From top left to bottom right: 0, 18, 24 and 48 h. Values in 
the quadrants represent the frequency of each population within the singlets events. Horizontal 
axis represents red fluorescence emission, corresponding to RFP signal (MPAO1). Vertical axis 
represents green fluorescence emission, corresponding to GFP signal (ΔfpvA). 
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Appendix Figure 5: Analysis of mutant relative fitness in iron limited CAA in the 
presence or absence of 20 µg/mL of gentamicin: The log10 relative fitness (v) of mutants 
was calculated as v = [log10(t2)(1− log10(t1))]/[log10(t1)(1− log10(t2))], where t1 is the initial 
proportion of mutants and t2 is their final proportion. The fitness value of v therefore signifies 
whether mutants increased in frequency (v > 0), decreased in frequency (v < 0) or remained at the 
same frequency (v = 0) over the competitive period. Error bars represent CI 95% of the mean 
from three biological replicates with alternate fluorescent tags (GFP and RFP). 
